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A B S T R A C T
Background
Intermittent locking of central venous catheters (CVCs) is undertaken to help maintain their patency. There are systematic variations
in care: some practitioners use heparin (at different concentrations), whilst others use 0.9% NaCl (normal saline). This review looks
at the effectiveness and safety of intermittent locking with heparin compared to 0.9% NaCl to see if the evidence establishes whether
one is better than the other. This work is an update of a review first published in 2014.
Objectives
To assess the effectiveness and safety of intermittent locking of CVCs with heparin versus normal saline (NS) in adults to prevent
occlusion.
Search methods
The Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (last searched 11 June 2018) and the Cochrane
Central Register of Controlled Trials (CENTRAL; 2018, Issue 5). Searches were also carried out in MEDLINE, Embase, CINAHL,
and clinical trials databases (11 June 2018).
Selection criteria
We included randomised controlled trials in adults ≥ 18 years of age with a CVC that compared intermittent locking with heparin at
any concentration versus NS. We applied no restriction on language.
Data collection and analysis
Two review authors independently selected trials, assessed quality, and extracted data. We contacted trial authors to retrieve additional
information, when necessary. We carried out statistical analysis using Review Manager 5 and assessed the overall quality of the evidence
supporting assessed outcomes using GRADE. We carried out prespecified subgroup analysis.
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Main results
We identified five new studies for this update (six prior studies were included in the original review), bringing the number of eligible
studies to 11, with a total of 2392 participants. We noted differences in methods used by the included studies and variation in heparin
concentrations (10 to 5000 IU/mL), time to follow-up (1 to 251.8 days), and the unit of analysis used (participant, catheter, line
access).
Combined results from these studies showed fewer occlusions with heparin than with NS (risk ratio (RR) 0.70, 95% confidence interval
(CI) 0.51 to 0.95; P = 0.02; 1672 participants; 1025 catheters from 10 studies; I² = 14%) and provided very low-quality evidence.
We carried out subgroup analysis by unit of analysis (testing for subgroup differences (P = 0.23; I² = 30.3%). When the unit of analysis
was the participant, results show no clear differences in all occlusions between heparin and NS (RR 0.79, 95% CI 0.58 to 1.08; P =
0.15; 1672 participants; seven studies). Subgroup analysis using the catheter as the unit of analysis shows fewer occlusions with heparin
use (RR 0.53, 95% CI 0.29 to 0.95; P = 0.03; 1025 catheters; three studies). When the unit of analysis was line access, results show
no clear differences in occlusions between heparin and NS (RR 1.08, 95% CI 0.84 to 1.40; 770 line accesses; one study).
We found no clear differences in the duration of catheter patency (mean difference (MD) 0.44 days, 95% CI -0.10 to 0.99; P = 0.11;
1036 participants; 752 catheters; six studies; low-quality evidence).
We found no clear evidence of a difference in the following: CVC-related sepsis (RR 0.74, 95% CI 0.03 to 19.54; P = 0.86; 1097
participants; two studies; low-quality evidence); mortality (RR 0.76, 95% CI 0.44 to 1.31; P = 0.33; 1100 participants; three studies;
low-quality evidence); haemorrhage at any site (RR 1.32, 95% CI 0.57 to 3.07; P = 0.52; 1245 participants; four studies; moderate-
quality evidence); or heparin-induced thrombocytopaenia (RR 0.21, 95% CI 0.01 to 4.27; P = 0.31; 443 participants; three studies;
low-quality evidence).
Themain reasons for downgrading the quality of evidencewere unclear allocation concealment, imprecision, and suspicionof publication
bias.
Authors’ conclusions
Given the very low quality of the evidence, we are uncertain whether intermittent locking with heparin results in fewer occlusions than
intermittent locking with NS. Low-quality evidence suggests that heparin may have little or no effect on catheter patency. Although
we found no evidence of differences in safety (sepsis, mortality, or haemorrhage), the combined trials are not powered to detect rare
adverse events such as heparin-induced thrombocytopaenia.
P L A I N L A N G U A G E S U M M A R Y
Heparin versus normal saline locking for prevention of occlusion in central venous catheters in adults
Background
Central venous catheters are tubes (also called ’lines’) temporarily implanted into patients when frequent intravenous access is needed.
They can be used for monitoring patients in intensive care, for giving drugs or chemotherapy, or for providing intravenous nutrition.
A Hickman line is an example of a central venous catheter. Blood clots and other factors can block these catheters. Blood clots in or on
a catheter can also become infected or can travel to the lungs (this is known as a ’pulmonary embolism’). Heparin is a drug that helps
to prevent blood clotting, so it may help prevent catheters from blocking or from causing pulmonary embolism. However, heparin
can also cause bleeding, allergic reactions, and a drop in the number of platelets in the blood. When a catheter is not in use, a fluid is
injected into the catheter until it is next used. This is called locking the catheter. Fluid used for locking is often heparin or normal saline
(a sterile solution of salt in water at a concentration suitable for the blood). We did this review to find out whether locking catheters
with heparin was better than locking them with saline to avoid blockages, and to determine how safe each method is. This work is an
update of a review first published in 2014.
Study characteristics and main findings
For this update (most recent search performed 11 June 2018), we found five more studies, giving us a total of 11 studies involving 2392
participants. Our updated review found that locking catheters with heparin may or may not prevent blocking better than flushing with
normal saline. We saw little or no difference in duration of catheter patency (length of time catheter remained unobstructed), rate of
2Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
infection, mortality, bleeding, or heparin-induced fall in platelet count (thrombocytopaenia). We detected no effect with increasing
concentrations of heparin dose.
Quality of the evidence
The quality of the evidence ranged from very low to moderate for the main outcomes. We downgraded the quality of evidence owing
to risk of bias and imprecision, as the pooled result included an effect of both benefit and harm and the suggestion of publication bias.
To sum up, we are uncertain on the effects of heparin compared to normal saline and the findings should be interpreted with caution.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Heparin versus normal saline solution locking for prevention of occlusion in central venous catheters in adults
Patient or population: adults with central venous catheters
Settings: hospital
Intervention: heparin
Comparison: normal saline (0.9%NaCl)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Normal saline
(NS, 0.9% NaCl)
Heparin
Occlusion of CVC
(combining participant
and catheter as unit of
analysis)
Blood withdrawing
Follow-up:1 to 231 days
Study population RR 0.70
(0.51 to 0.95)
1672 part icipants, 1025
catheters
(10 RCTs)
⊕©©©
Very lowa,b
NNTB 42
(32 to 250)
Considering only par-
ticipant as unit of anal-
ysis
(7 studies, 1672 part ic-
ipants):
RR 0.79 (95%CI 0.58 to
1.08)
Considering
only catheter as unit of
analysis
(3 studies, 1025
catheters):
RR 0.53 (95%CI 0.29 to
0.95)
103 per 1000 77 per 1000
(62 to 86)
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Duration of catheter
patency
(days; combining par-
ticipant and catheter as
unit of analysis)
Blood withdrawing
Follow-up: 3 to 180
days
Study population 1788
(6 RCTs)
⊕⊕©©
Lowc
No clear dif f erence in
catheter patency was
shown. This was less
than 1 day longer with
heparin locking
Considering only par-
ticipant as unit of anal-
ysis
(4 studies, 1036 part ic-
ipants):
MD 0.66 (95% CI -0.66
to 1.97)
Considering
only catheter as unit of
analysis
(2 studies, 752
catheters):
MD 0.40 (95% CI -0.20
to 0.99)
Mean catheter patency in the heparin group was
0.44 days higher
(-0.1 lower to 0.99 higher) than in the NS group
Mean catheter patency in the saline group was
9 days (8.36 to 9.7 days)
CVC- related sepsis
(participant as unit of
analysis)
Posit ive microbiologi-
cal culture
Follow-up: 22 to 180
days
Study population RR 0.74
(0.03 to 19.54)
1097
(2 RCTs)
⊕⊕©©
Lowd
No clear evidence of a
dif ference in sepsis be-
tween locking methods
was shown
11 per 1000 8 per 1000
(0 to 212)
Mortality
Follow-up: 17 to 180
days
Study population RR 0.76
(0.44 to 1.31)
1100
(3 RCTs)
⊕⊕©©
Lowa
No clear evidence of a
dif ference in mortality
between locking meth-
ods was shown
52 per 1000 40 per 1000
(23 to 68)
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Haemorrhage at any
site
Follow-up: 1 to 180
days
Study population RR 1.32
(0.57 to 3.07)
1245
(4 RCTs)
⊕⊕⊕©
Moderatee
No clear evidence of
a dif ference in haemor-
rhage between locking
methods was shown13 per 1000 17 per 1000
(7 to 39)
Heparin- induced
thrombocytopaenia
Follow-up: 7 to 22 days
Study population RR 0.21
(0.01 to 4.27)
443
(3 RCTs)
⊕⊕©©
Lowf
No clear evidence of
a dif ference in HIT be-
tween locking methods
was shown. Studies are
likely to be underpow-
ered to detect low ad-
verse events
9 per 1000 2 per 1000
(0 to 38)
* The assumed risk (e.g. median control group risk across studies) was calculated f rom the included studies. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; CVC: central venous catheter; HIT: heparin-induced thrombocytopaenia; MD: mean dif ference; NNTB: number needed to treat for an addit ional benef icial
outcome; NS: normal saline; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aWe downgraded the quality of evidence by one level for risk of bias due to unclear allocat ion concealment and by one
addit ional level for imprecision because the 95% CI included both no harm and harm.
bWe downgraded the quality of evidence by one level owing to high risk of suspected publicat ion bias (Figure 1).
cWe downgraded by one level owing to risk of bias due to uncertain allocat ion concealment and by one addit ional level for
imprecision because the pooled result included benef it and harm.
dWe downgraded by two levels owing to the fact that the total number of events was less than 400, the pooled result included
benef it and harm, and conf idence intervals were very wide.
eWe downgraded the quality of evidence by one level for imprecision because the 95% CI included both benef it and harm.
fWe downgraded the quality of evidence by two levels owing to the fact that only one study detected HIT (Schallom 2012),
with a f inding that is counterintuit ive (lower HIT in pat ients treated with heparin locking). In addit ion, invest igators removed
seven part icipants f rom the heparin locked catheter group because of concerns over bleeding or HIT. Moreover, the studies
are likely to be underpowered to detect low adverse events, the conf idence interval is large, and therefore uncertainty is high.
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B A C K G R O U N D
Description of the condition
Vascular access devices (VADs) are commonly used in health care.
They encompass a wide range of devices that include, among oth-
ers, central venous catheters (CVCs). A CVC is a catheter with a
tip that lies within the proximal third of the superior vena cava,
the right atrium, or the inferior vena cava. Catheters can be in-
serted through a peripheral vein or a proximal central vein, most
commonly the internal jugular, subclavian, or femoral vein. Four
types of CVCs are available: non-tunnelled catheters, tunnelled
catheters (e.g.Hickman catheters, tunnelled dialysis catheters), pe-
ripherally inserted catheters, and totally implantable ports (port-
a-cath) (Smith 2013).
In the United States, more than five million CVCs are inserted
every year (Merrer 2001), leading to approximately 15 million
central line days per year in intensive care units (ICUs) (Mermel
2000). CVCs allowmeasurement of haemodynamic variables that
cannot bemeasured accurately by non-invasivemethods (although
some minimally invasive methods are now available), and they al-
low delivery of blood, medication, and nutritional support that
cannot be given safely through peripheral venous catheters. Un-
fortunately, use of CVCs is associated with adverse events. Among
them, mechanical complications during insertion (arterial punc-
ture, haematoma, and pneumothorax) in 5% to 29% (Eisen 2006;
McGee 2003), infectious complications in 5% to 26% (Merrer
2001; Raad 1997; Veenstra 1999), and thrombosis in 2% to 26%
(Lee 2007) are the most common.
To some extent, thrombi are formed on CVCs during the first few
hours of use in the form of fibrin tail, fibrin sheath, intraluminal
occlusion, or mural thrombus (Jonker 2010), and thrombosis of
large vessels occurs after long-term catheterisation (Valerio 1981).
The incidence of CVC-related thrombosis varies depending on
the patient’s condition, catheter tip position and diameter, side
and technique of insertion, and the chemical structure and nature
of the infusate, among other factors (Verso 2003). CVC-related
thrombosis represents an important source of morbidity and mor-
tality among affected patients, not only for its inherent risks but
also because thrombus creates a medium for bacterial proliferation
that promotes infection (Mermel 2000). Pulmonary embolism,
a severe medical condition, occurs in approximately 15% of pa-
tients with CVC-related upper extremity deep venous thrombosis
(Burns 2008).
To avoid thrombus formation in CVCs, clinicians are currently
applying several measures with different levels of success. Among
others, heparin-locking catheters (Bishop 2009), heparin-bonded
catheters (Shah 2008), systemic heparinisation with unfraction-
ated heparin or with low molecular weight heparin (Randolph
1998b), anticoagulation with warfarin (Bern 1990), or adminis-
tration of alteplase or urokinase, as in Hemmelgarn 2011 and Ray
1999, respectively, may be used. Heparin locking is themost com-
monly used procedure. According to some trial authors, the use of
heparin may be justified with some types of VADs when they are
not used frequently (Bishop 2009), but the efficacy of this practice
remains unproven (López-Briz 2005).
Description of the intervention
Heparin locking essentially consists of filling the lumens of CVCs
with solutions of unfractionated heparin of varying strength.
How the intervention might work
Use of CVCs predisposes to vascular thrombosis via vessel wall
injury (during catheter placement), hypercoagulability, and alter-
ations in normal blood flow. The balance between haemostatic sys-
tems producing thrombi and fibrinolytic systems dissolving them
regulates blood vessel lumen patency, but placement of a CVC can
alter this fine-tuned process, leading to a persistent thrombotic
state. Catheter composition also plays a role in this thrombotic sit-
uation, allowing adsorption of fibrin and fibrinogen on its surface,
thereby worsening the problem (Jacobs 2003). The anticoagulant
properties of heparin have led clinicians to use heparin flushes in
an attempt to prevent thrombus formation and to prolong the
duration of catheter patency between uses. However, this phys-
iopathological rationale may be wrong when applied to peripheral
venous catheters, for which no benefit in using heparin locking
versus normal saline (NS) locking has been demonstrated, as two
published systematic reviews have independently shown (Goode
1991; Randolph 1998a).
Why it is important to do this review
Bishop and colleagues reported in 2009 that heparin locking
of catheters is a standard practice in the maintenance of CVCs
(Bishop 2009), but the effectiveness of this practice so far has
not been established in a systematic review. Moreover, variation
in nursing practice is considerable because current guidelines pro-
vide conflicting recommendations about locking frequency and
heparin concentration and volume (Mitchell 2009). A recent sur-
vey conducted in ICUs in the United States shows that 64.6% of
respondents used NS and 31% used heparin (Sona 2012). The
concentrations of heparin most commonly used were 100 IU/mL
(37.5%) and 10 IU/mL (29.7%), and the most common intervals
for locking catheters were every eight hours and after each use
(74.4%). No information is available on CVC maintenance prac-
tices in other countries, so could clinical expertise be the guiding
principle on this topic?
There are reasons to think that heparin locking catheters might
be helpful. This makes pathophysiological sense. One systematic
review studied the benefits of heparin in central venous and pul-
monary artery catheters (Randolph 1998b). This paper showed
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that prophylactic systemic heparin decreases catheter-related ve-
nous thrombosis (risk ratio (RR) 0.43, 95% confidence interval
(CI) 0.23 to 0.78) and bacterial colonisation of CVCs (RR 0.18,
95% CI 0.06 to 0.60) and may decrease catheter-related bacter-
aemia (RR 0.26, 95%CI 0.07 to 1.03). Randolph 1998b included
combined data from trials using several doses of systemic prophy-
lactic heparin, including unfractionated heparin (treatment regi-
mens of 1 IU/kg, 3 IU/kg, 50 IU q12h, and 5000 IU intermit-
tently), low molecular weight heparin (2500 IU given subcuta-
neously daily), or heparin-bonded catheters and did not include
trials that provided periodic flushing of CVCs with heparin.
However, there are also potential harms associated with heparin
use. Heparin-induced thrombocytopaenia (HIT), a severe im-
munological drug reaction known to cause arterial and venous
thromboembolism without haemorrhage, raises serious concerns
regarding the use of heparin (Warkentin 2007). Exposure of sur-
gical patients to unfractionated heparin for longer than four days
implies an overall risk of HIT of 2.6% (Martel 2005). This ad-
verse effect of heparin treatment is a common late-onset compli-
cation that can develop five or more days after initiation of the
drug. Another potential harm that may be associated with heparin
use is the incidental administration of a heparin bolus through a
catheter line intended for heparin locking.
From an economic point of view, avoiding heparin locking would
represent a very important cost savings (Sona 2012). Another sys-
tematic review estimated yearly savings of USD109 million to
USD218 million when peripheral venous lines were flushed with
NS instead of heparin (Goode 1991).
In summary, the effectiveness of heparin locking of CVCs has not
yet been demonstrated, and wide systematic variations in both
guideline recommendations and practice have surrounded its use.
Moreover, use of heparin is not free of risk and has a consider-
able economic impact. We developed a protocol and performed a
systematic review about this topic (López-Briz 2010; López-Briz
2014). This is the first update of our review first published in
2014.
O B J E C T I V E S
To assess the effectiveness and safety of intermittent locking of
central venous catheterswith heparin versus normal saline in adults
to prevent occlusion.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) of heparin
locking versus NS solution locking of central venous catheters
(CVCs) in adults. We excluded studies when researchers used al-
ternative methods of randomisation (quasi-randomised), such as
alternate days of the week, odd and even numbers, dates of birth,
hospital numbers, or historical controls.
Types of participants
We included studies of adults 18 years of age or older with a CVC.
We excluded from this review studies on infants and children, as
they are the topic of another Cochrane review (Bradford 2015).
Types of interventions
Interventions included intermittent locking with heparin (any
dose with or without systemic drugs) compared with NS solution.
All locking protocols were acceptable for inclusion.
Types of outcome measures
Primary outcomes
• Occlusion of CVCs (defined as inability to infuse fluids
through the catheter because of blockage)
• Duration (in days) of catheter patency
Secondary outcomes
• Episodes of CVC-related sepsis and CVC-related
colonisation (CVC-related sepsis is defined as the presence of
symptoms and signs suggestive of sepsis, accompanied by positive
blood cultures obtained from a normally sterile site different
from the CVC or CVC tip, each growing the same micro-
organism; CVC-related colonisation is defined as the presence of
micro-organisms in the CVC only and not at another sterile site)
• Mortality
• Haemorrhage from any site in the body
• Heparin-induced thrombocytopaenia (HIT) (development
of thrombocytopaenia after heparin locking of a CVC in an
adult with a previously normal platelet count after exclusion of
all other causes of thrombocytopaenia, along with a positive
antibody test)
• CVC-related thrombosis (determined by colour-coded
Doppler ultrasonography, venography, computerised
tomography, or magnetic resonance venography)
• Number of additional CVC insertions
• Abnormality of coagulation profile
• Allergic reactions to heparin
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Search methods for identification of studies
We applied no restriction on language of publication.
Electronic searches
The Cochrane Vascular Information Specialist (CIS) searched the
SpecialisedRegister (last searched 11 June 2018) and theCochrane
Central Register of Controlled Trials (CENTRAL; 2018, Issue 5).
See Appendix 1 for the search strategy used for CENTRAL.
The review authors and the CIS also searched MEDLINE, Em-
base, the Cumulative Index to Nursing and Allied Health Litera-
ture (CINAHL), and clinical trials registries (last searched 11 June
2018).
We have presented in Appendix 2, Appendix 3, Appendix 4,
Appendix 5, and Appendix 6 the search strategies used.
Searching other resources
We searched the reference lists of relevant studies identified
through the electronic searches.
Data collection and analysis
Selection of studies
Two review authors (ELB and VRG) independently read the ab-
stract and, if necessary, the full text of potentially relevant refer-
ences, to identify studies that needed to be further examined. We
excluded letters, editorials, commentaries, reviews, and lectures
that did not contain original research data. We contacted authors
of unpublished and ongoing trials to obtain further information.
When differences in opinion arose, we consulted a third review
author (RCS).
Data extraction and management
Three review authors (ELB, VRG, and RCS) independently ex-
tracted data regarding populations, interventions, and relevant
outcomes, using the standard Cochrane Vascular forms for di-
chotomous data and continuous data.We contacted study authors
to obtain additional data, if necessary (Goosens 2013; Schallom
2012).
Assessment of risk of bias in included studies
We assessed the risk of bias in included studies by using standard-
ised criteria from Cochrane for the following (Higgins 2011).
• Adequacy of random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective reporting.
• Other bias.
Measures of treatment effect
We used risk ratio (RR) with 95% confidence interval (CI) and
number needed to treat for an additional beneficial outcome
(NNTB) to measure any effect on dichotomous variables (i.e. oc-
clusion of CVCs, mortality, adverse events, etc.). We calculated
NNTB values from the RR according to the formula NNTB
(or number needed to treat for an additional harmful outcome
(NNTH)) = 1/ACR*(1-RR), for which ACR is the assumed con-
trol risk (McQuay 1997).
Unit of analysis issues
In the protocol version, when we planned the present systematic
review, we assumed that the unit of analysis would be the par-
ticipant. Once we performed the literature search, we found that
the unit of analysis used by researchers was the participant or the
catheter or line access (i.e. each time a line is used to provide drugs,
blood, etc.). We performed analysis separately for each different
unit of analysis for outcomes that could have been influenced by
the unit of analysis (occlusions and patency), if sufficient data were
available. The main analyses stratify studies by unit of analysis
type, but we also reported the main results irrespective of the unit
of analysis.
For secondary outcomes, when considering adverse effects, we
used the participant as the denominator for analysis.
Dealing with missing data
We contacted the principal investigators of two studies to request
additional data (Goosens 2013; Schallom 2012). These study au-
thors provided relevant data that were later published.
Assessment of heterogeneity
We attempted to explain relevant clinical, methodological, or sta-
tistical heterogeneity using forest plots, and we quantified het-
erogeneity using the I² statistic (Higgins 2003). Thresholds for
interpretation of I² can be misleading in that the importance of
inconsistency depends on several factors. Higgins 2011 prepared
the following rough guide to interpretation.
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: shows considerable heterogeneity.
Assessment of reporting biases
We assessed reporting bias using funnel plots, as we identified a
sufficient numbers of studies.
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Data synthesis
We summarised data statistically, if possible. We performed statis-
tical analysis according to the statistical guidelines referenced in
the current version of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). We used Review Manager
5 for review production and data analysis. We used a random-
effects model. We planned to use a fixed-effect model to pool data
when statistical heterogeneity was low, as in our previous review
(López-Briz 2014). However, we decided to use a random-effects
model, even though I² values were low, because although the same
drug was used across trials (heparin), we noted clear clinical het-
erogeneity in the study methods applied (i.e. different doses with
systemic heparin or not, different follow-up times, different kinds
of patients, etc.).
Subgroup analysis and investigation of heterogeneity
For the primary outcomes, we performed subgroup analyses for
each different unit of analysis. The incidence of CVC-related
thrombosis varies depending on clinical type of the participant
(onco-haematological, critical, on dialysis, etc.), CVC implanta-
tion site, CVC type, and infusate-related factors. We planned to
perform subgroup analyses to take these factors into account, if
sufficient data were available.
Sensitivity analysis
We carried out sensitivity analyses to explore the robustness of
results by investigating the influence of the following factors on
effect size.
• Published or unpublished studies.
• Quality of studies.
• Weight of different studies.
• Different measures of effect size (odds ratio (OR) and risk
ratio (RR)).
’Summary of findings’ table
We created Summary of findings for the main comparison for the
comparison heparin versus NS intermittent locking for preven-
tion of occlusion in central venous catheters in adults. We used
GRADEpro GDT software to present the main findings of the re-
view (gradepro.org) (GRADEproGDT 2015).We judged the out-
comes of CVC occlusion, duration of catheter patency, CVC-re-
lated sepsis, mortality, haemorrhage, and heparin-induced throm-
bocytopaenia to be the most clinically relevant to healthcare pro-
fessionals and patients. For each outcome, we calculated assumed
control intervention risks from the mean number of events re-
ported in the control groups of selected studies.Weused the system
developed by the GRADE Working Group to grade the quality
of evidence as high, moderate, low, or very low, based on within-
study risk of bias, directness of evidence, heterogeneity, precision
of effect estimates, and risk of publication bias (Guyatt 2008).
R E S U L T S
Description of studies
Results of the search
See Figure 2.
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Figure 2. Study flow diagram.
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Included studies
Five new studies met the inclusion criteria for this update (Beigi
2014;DalMolin 2015;Heidari 2015; Lyons 2014;Mahesh 2014),
bringing the total number of included studies to 11, with a to-
tal of 2392 participants (Beigi 2014; Bowers 2008; Dal Molin
2015; Goosens 2013; Heidari 2015; Kaneko 2004; Lyons 2014;
Mahesh 2014; Pumarola 2007; Rabe 2002; Schallom 2012). See
Characteristics of included studies.
Beigi 2014 was a single-blinded randomised controlled trial with
100 participants with chronic kidney disease. Researchers ran-
domly assigned participants to locking with heparin (1000 IU)
versus NS. The unit of analysis was the participant. Only three in
the heparin group and one in the NS group withdrew. We sent
a letter to study authors to request more information. Length of
follow-up was 24 hours.
Bowers 2008 conducted a single-centre randomised study in 102
adult participants with single-lumen peripherally inserted central
catheters (PICCs) with luer-activated devices. Trial authors used
a random block design with allocation concealment to randomly
assign participants to receive NS or heparin lock flush (100 USP
U/mL). The main outcome studied was occlusion rate, and the
secondary outcome was duration of PICCs (in days). The unit of
analysis was the participant for occlusion rate as well as for patency.
All participants completed the study (50 in the NS group and 52
in the heparin group).
Dal Molin 2015 was a multi-centre, open-label randomised trial
with 430 oncological participants. Investigators randomly as-
signed participants to locking with heparin 5 mL (50 IU) versus
NS 5 mL. Trial authors used the participant as the unit of analysis
for occlusion. Study authors reported 5% withdrawals from the
NS group and 2.5% from the heparin group without providing
details.
Goosens 2013 conducted a randomised controlled open-label
non-inferiority trial in 802 participants older than one year sched-
uled for first insertion of a totally implantable venous access de-
vice (TIVAD) through the superior vena cava (SVC) system,
with an onco-haematological malignancy and with sufficient life
expectancy to complete the planned follow-up of 180 days at
the study centre. After randomisation via computerised random
number generation, researchers assigned 398 participants to re-
ceive an NS lock and 404 to receive a heparin lock in a non-
blinded manner. Although participants were randomly assigned,
the main unit of analysis was the number of catheters accessed.
However, Goosens provided additional information about occlu-
sions per participant. Participants who had difficulties with aspira-
tion through the catheter were registered. Investigators considered
outcomes of withdrawal occlusion, catheter-related bacteraemia,
and catheter duration within 180 days (unit of analysis - partici-
pant), as well as adverse events. Study authors also provided data
on sepsis, thrombosis, and mortality. We requested information
on data for adult participants, and Dr Goosens responded: “Only
3.5% of patients were < 18 years old, given that small number we
didn’t perform any sub analysis. Moreover we don’t presume any
difference in results between adults and peds” [sic].
Heidari 2015 conducted a double-blinded RCT in 84 participants
from the intensive care unit. This study compared a flush of 3
mL of heparin saline solution (10 IU/mL) versus NS locking. The
main outcome was CVC patency, and the unit of analysis chosen
was the participant. We requested additional information from
study authors. Follow-up was 21 days.
Kaneko 2004 performed a single-centre, open-label, randomised
controlled clinical trial in adult participants with an inserted dou-
ble-lumen CVC. This study compared a flush of 20 mL of NS
versus a flush of 20 mL of NS followed by locking with 2 mL
heparin (1000 IU/mL). Researchers used low molecular weight
heparin at 8 IU/kg/h during each haemodialysis session. They ran-
domly allocated 48 participants to the NS (26) or heparin group
(22). They studied the outcomes days of catheter survival and
thrombotic occlusion (both considered the participant as the unit
of analysis), as well as coagulation analytical parameters such as
activated coagulation time, activated partial thromboplastin time,
and prothrombin time.
Lyons 2014 performed a single RCT on 90 participants from
home care and tried to find the most effective locking solution for
maintenance of PICCs. This study compared three arms: 10mL of
NS, 5mL of low-dose heparin (10 IU/mL), and 3mL of high-dose
heparin (100 IU/mL). The main outcome was the development
of patency-related complications (sluggishness, occlusions, etc.),
and researchers used the participant as the unit of analysis. One
participant in the NS group and one in the high-dose heparin
group withdrew. We sent a letter to study authors to request more
information.
Mahesh 2014 performed an RCT in 100 participants from the
Respiratory Intensive Care Unit with CVC with triple lumen.
This study compared heparin (3 mL, 10 IU/ mL) versus NS (10
mL) flushes every eight hours. The primary outcome of the study
was lumen non-patency, defined as inability to both withdraw
blood and flush through a lumen, and the unit of analysis was
the participant. Researchers reached the conclusion of lumen non-
patency after the following interventions: (1) if the lumen could
not be flushed, the participant was repositioned and the flush re-
attempted; and (2) if the lumen still could not be flushed, the
syringe was changed and the flush was re-attempted. Investigators
assessed the secondary outcome, HIT, using daily platelet count
starting on day 4 from the time of giving heparin flushes to all
participants in the heparin group.
Pumarola 2007 carried out a two-phase clinical trial in a polyva-
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lent ICU. Participants were adults with multiple pathological pro-
cesses inwhom a three-lumenCVChad been inserted. Researchers
used a registered software program (Aleator; Aleator SRL, Buenos
Aires, Argentina) for randomisation. However, the study was not
blinded. In the first phase, trialists compared two concentrations
of heparin (20 IU/mL and 100 IU/mL), establishing patency at 24
hours after catheter implantation and at discharge. In the second
phase, they compared heparin at a concentration of 100 IU/mL
versus NS and assessed patency at 24 hours, at 72 hours, and at
discharge. Only this second phase fulfilled our inclusion criteria.
Study authors assessed 95 CVCs during this phase (38 in the hep-
arin group and 57 in the NS group) for occlusion rates and mean
days of catheter duration, using the catheter as the unit of analysis
for both.
Rabe 2002 studied 99 three-lumen CVCs inserted into 91 adult
participants locked with one of the following solutions: NS, hep-
arin (5000 IU/mL), or vitamin C (200 mg/mL). Researchers as-
signed catheters randomly (using a list of random numbers pre-
pared by the study authors) to one of three groups. They assessed
patency every two days to a maximum of 20 days. Study outcomes
included thrombotic obstruction and catheter survival, with the
catheter used as the unit of analysis.
Schallom 2012 conducted a single-centre study wherein re-
searchers randomly assigned patients in the ICU with a newly
placed three- or four-lumen CVC (simple randomisation, se-
quence concealed) to be flushed with NS or with heparin (10 IU/
mL every 8 hours). Among the randomly assigned participants,
295 had at least one lumen with a minimum of two flushes, re-
sulting in 326 catheters (170 allocated to the NS group and 156
to the heparin group) with 709 lumens (395 in the NS group
and 314 in the heparin group). The primary outcome was lack
of lumen patency (unit of analysis was the catheter). Secondary
outcomes included rates of loss of blood return, flush failure, HIT,
and catheter-related bloodstream infection.
Excluded studies
We excluded seven additional studies from this update (Chen
2014; Han 2016; Liang 2015; NCT03114722; Phulara 2018; Xu
2017; Ziyaeifard 2015). The total number of excluded studies
in the current review is 179. We excluded these studies for the
following reasons.
• Studies did not meet the criteria established for intervention
(heparin) or comparison (0.9% NaCl sterile solution).
• Studies focussed on peripheral catheters.
• Studies focussed on arterial catheters.
• Studies did not provide data stratified by arterial and
venous catheters.
We excluded some studies for more than one reason.
See the Characteristics of excluded studies section for further de-
tails.
Ongoing studies
We identified three new studies as ongoing (NCT02354118;
NCT02923830; RBR-3ht499). See Characteristics of ongoing
studies for further details.
Studies awaiting classification
We identified two studies as awaiting classification (Klein 2017;
Klein 2018). See Characteristics of studies awaiting classification
for further details.
Risk of bias in included studies
Figure 3 and Figure 4 show risk of bias according to the quality of
included trials.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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We show summarised results for main outcomes (occlusions and
days of patency) and by bias domain.
Occlusion of CVCs
Unit of analysis: participant
Seven trials assessed this outcome (Beigi 2014; Bowers 2008; Dal
Molin 2015; Goosens 2013; Kaneko 2004; Mahesh 2014; Lyons
2014). We judged the first four to be at low risk for random
sequence generation: Beigi 2014 (random allocation numbers);
Bowers 2008 (“A random block design with concealment was
used”); Dal Molin 2015 (“A random allocation sequence was cre-
ated using a computerized procedure on-line”); and Goosens 2013
(randomisation computer generated). We assessed the remaining
three as having unclear risk.
Unit of analysis: catheter
Three trials assessed this outcome, and we rated them as having
low risk of bias for random sequence generation: Pumarola 2007
(randomisation computer generated); Rabe 2002 (randomisation
list prepared by study authors using a “random number genera-
tor”); and Schallom 2012 (computerised random number gener-
ator in MS Excel used by investigators).
Unit of analysis: line access
Only Goosens 2013 assessed this outcome. This trial performed
computer-generated randomisation, so we rated it as having low
risk of bias for random sequence generation.
Patency
Unit of analysis: participant
Four studies assessed this outcome (Bowers 2008; Goosens 2013;
Heidari 2015; Kaneko 2004). According to random sequence gen-
eration, we rated Bowers 2008, Goosens 2013, and Heidari 2015
as having low risk of bias, whereas we rated Kaneko 2004 as hav-
ing unclear risk of bias because methods were unclear or were not
described.
Unit of analysis: catheter
Two studies assessed patency using the catheter as the unit of
analysis (Pumarola 2007; Schallom2012).We rated both as having
low risk of bias according to random sequence generation.
CVC-related thrombosis
Two trials assessed this outcome. Goosens 2013 used computer-
generated randomisation, andSchallom 2012 used a computerised
random number generator inMS Excel, so we rated both as having
low risk for random sequence generation.
CVC-related sepsis
Two trials assessed this outcome. Goosens 2013 used computer-
generated randomisation, andSchallom 2012 used a computerised
random number generator inMS Excel, so we rated both as having
low risk for random sequence generation.
Mortality
Three trials assessed this outcome. Goosens 2013 used computer-
generated randomisation; Pumarola 2007 used computer-gener-
ated randomisation via the software Aleator.We rated both as hav-
ing low risk of bias for random sequence generation. Kaneko 2004
provided insufficient information about the sequence generation
process, and we judged this study to be at unclear risk of bias.
Haemorrhage from any site in the body
Four trials assessed this outcome (Beigi 2014; Goosens 2013;
Kaneko 2004; Schallom 2012). Beigi 2014 used random alloca-
tion number, Goosens 2013 used computer-generated randomi-
sation, and Schallom 2012 used a computerised random number
generator in MS Excel, so we rated these studies as having low risk
of bias for random sequence generation. We rated Kaneko 2004
as having unclear risk of bias because Information was insufficient
to permit judgement.
Heparin-induced thrombocytopaenia
Three studies reported heparin-induced thrombocytopaenia:
Kaneko 2004, Mahesh 2014, and Schallom 2012. We rated only
Schallom 2012 as having low risk of bias, and we judged Kaneko
2004 and Mahesh 2014 to have unclear risk of bias.
Allocation
Seven studies provided insufficient information about allocation
concealment, sowe assessed the risk of selection bias for these stud-
ies as unclear (Beigi 2014; Bowers 2008; Heidari 2015; Kaneko
2004;Mahesh 2014; Pumarola 2007; Rabe 2002). Pumarola 2007
reported a method of closed envelopes, but it remains unclear
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whether the envelopes were opaque or sealed to conceal informa-
tion. Goosens 2013 concealed the allocation sequence from re-
searchers who enrolled participants by using sequentially num-
bered participant cards stored in a separate room; Schallom 2012
stated that the allocation sequence was concealed from the re-
searcher enrolling participants; Dal Molin 2015 used a web-based
method to conceal allocation; and Lyons 2014 used a sequentially
numbered, opaque sealed envelope method, so we assessed these
studies as having low risk of selection bias.
Blinding
Eight studies were open-label or did not blind participants or re-
search staff to the intervention received by participants. We rated
these studies as having high risk of performance and detection bias
(Bowers 2008; Dal Molin 2015; Goosens 2013; Kaneko 2004;
Mahesh 2014; Pumarola 2007; Rabe 2002; Schallom 2012). Beigi
2014 and Lyons 2014 used single-blinding, and we classified their
risk of bias as unclear. Heidari 2015 was at low risk of bias as
both participants and researchers were unaware of which locking
fluid was used (solution was made up by nurses). However, nei-
ther occlusion nor patency was likely to be influenced by lack of
blinding. We judged that the secondary outcomes, namely, CVC-
related thrombosis, episodes of CVC-related sepsis and colonisa-
tion, numbers of additional CVC insertions, mortality, coagula-
tion profile, HIT, and allergic reactions to heparin and haemor-
rhage, were also unlikely to be influenced by lack of blinding.
Incomplete outcome data
We considered Beigi 2014 (two in heparin groups and one in saline
group withdrew), Bowers 2008 (no withdrawals), DalMolin 2015
(five participants in heparin group and 10 in saline group with-
drew), Heidari 2015 (no withdrawals), Mahesh 2014 (no with-
drawals), Lyons 2014 (no withdrawals), and Schallom 2012 (no
withdrawals) to have low risk of attrition bias because missing out-
come data were few and were balanced in numbers across inter-
vention groups, and reasons for missing data were similar across
groups.
Researchers in the Rabe 2002 and Goosens 2013 studies insuffi-
ciently reported attrition or exclusions to permit judgement, and
information about the number of catheters losing patency in each
treatment group was lacking in Rabe 2002. So, we rated both of
these studies as having unclear risk of attrition bias.
We rated both Kaneko 2004 and Pumarola 2007 as having high
risk of bias. Kaneko 2004 reported 40% withdrawals in the hep-
arin group (9/22) and 30% in the NS group (8/26) and provided
unclear reasons for withdrawal. Meanwhile, Pumarola 2007 re-
ported a withdrawal rate of 69.6% (87/125) in the heparin group
and 54.4% (68/125) in the NS group; the main reason for with-
drawal was cancellation of the procedure (74/125 and 52/125,
respectively).
Selective reporting
Dal Molin 2015, Goosens 2013, and Lyons 2014 reported all
expected outcomes, so we rated these studies as having low risk of
reporting bias. The remaining studies were at unclear risk owing
to lack of available protocols or insufficient information retrieved
from researchers (Beigi 2014; Bowers 2008;Heidari 2015; Kaneko
2004;Mahesh 2014; Pumarola 2007;Rabe 2002; Schallom2012).
Other potential sources of bias
Pumarola 2007 may be underpowered. Researchers analysed only
38 and 57 catheters per group, but the predetermined sample size
was 185 catheters per group; trialists stopped the study early for 74
and 52 catheters in the heparin and NS groups, respectively, but
did not provide the reason for this. Therefore we rated risk of other
bias as high. In Goosens 2013, 3.5% of participants were children
and study authors did not perform separate analyses; therefore we
rated risk of other bias as unclear. The remaining studies were at
low risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison Heparin
versus normal saline solution locking for prevention of occlusion
in central venous catheters in adults
Primary outcomes
Occlusion of CVCs
Ten studies (1672 participants, 1025 catheters) reported on oc-
clusion of CVCs using either the participant or the catheter as the
unit of analysis, and we pooled results in the overall meta-analy-
sis (Beigi 2014; Bowers 2008; Dal Molin 2015; Goosens 2013;
Kaneko 2004; Lyons 2014; Mahesh 2014; Pumarola 2007; Rabe
2002; Schallom 2012). Results demonstrated a favourable effect
of heparin in preventing occlusion (risk ratio (RR) 0.70, 95% con-
fidence interval (CI) 0.51 to 0.95; P = 0.02; Analysis 1.1; Figure
5). Testing for subgroup differences showed little to no difference
between subgroups (P = 0.23; I² = 30.3). Using the calculator from
Chris Cates’ web page (nntonline.net/visualrx/), we found that
the number needed to treat for an additional beneficial outcome
(NNTB) was 42 (95% CI 32 to 250). The funnel plot that we
created for this outcome suggested that risk of publication bias
was present (Figure 1). We judged the quality of evidence for this
outcome to be very low. We downgraded the quality of evidence
by one level for risk of bias due to unclear allocation concealment,
by one more for imprecision because the 95% CI included both
benefit and no benefit, and by one more for suspicion of publica-
tion bias.
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Figure 5. Forest plot of comparison: 1 All occlusions, outcome: 1.1 All studies.
Seven studies (1672 participants) used the participant as the unit
of analysis (Beigi 2014; Bowers 2008; Dal Molin 2015; Goosens
2013; Kaneko 2004; Lyons 2014; Mahesh 2014). We noted no
clear evidence of an effect upon pooling this subgroup only (RR
0.79, 95% CI 0.58 to 1.08; I² = 7%; P = 0.37; Analysis 2.1).
We judged the quality of evidence to be low. We downgraded the
quality of evidence by one level for risk of bias due to unclear
allocation concealment and by one more for imprecision because
the 95% CI included both benefit and no benefit.
Three studies with 1025 participants used the catheter as the unit
of analysis (Pumarola 2007; Rabe 2002; Schallom 2012). Results
demonstrated a favourable effect of heparin (RR 0.53, 95% CI
0.29 to 0.95; I² = 0%; P = 0.03; Analysis 2.2). We used a Mantel-
Haenszel (M-H) random-effects model. Using the calculator from
Chris Cates’ web page (http://www.nntonline.net/visualrx/), we
found that the NNTBwas 71 (95% CI 47 to 667). We judged the
quality of evidence to be moderate. We downgraded the quality
of evidence by one level for risk of bias due to unclear allocation
concealment.
Only one study used line access as the unit of analysis (Goosens
2013). This study included 6137 observations and showed no
differences in the number of occlusions between heparin and NS
locking (RR 1.08, 95%CI 0.84 to 1.40). We judged the quality of
evidence to be moderate. We downgraded the quality of evidence
by one level for imprecision because the 95% CI included both
benefit and no benefit. Despite lack of blinding in this trial, we
decided not to downgrade quality because this would not affect
the occlusions. Dr Goosens kindly provided data from unit of
analysis participants and from unit of analysis lines accessed. To
prevent double counting, we decided not to include both types
of data in the overall results, and we used data only from unit of
analysis participants in the meta-analysis.
Duration (in days) of catheter patency
Wepooled six studieswith 1788participants (using the participant
or the catheter as the unit of analysis) and analysed results for
catheter patency duration (Bowers 2008; Goosens 2013; Heidari
2015; Kaneko 2004, Pumarola 2007; Schallom 2012). Data show
no difference in this outcome between heparin and NS groups
(mean difference (MD) 0.44, 95% CI -0.10 to 0.99; P = 0.11;
Analysis 3.1). Testing for subgroup differences showed little to no
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difference between the subgroups (P = 0.72; I² = 0; Figure 6).
We judged the quality of evidence to be low. We downgraded the
quality of evidence by one level for risk of bias due to unclear
allocation concealment and by one more for imprecision because
the 95% CI included both benefit and harm.
Figure 6. Forest plot of comparison: 3 All patency, outcome: 3.1 All studies.
Four studies with 1036 participants used the participant as the unit
of analysis for catheter patency duration (Bowers 2008; Goosens
2013; Heidari 2015; Kaneko 2004). We detected no clear differ-
ences between heparin and NS groups (MD 0.66, 95% CI -0.66
to 1.97; I² = 0%; P = 0.33; Analysis 4.1). We judged the quality
of evidence to be low. We downgraded the quality of evidence by
one level for risk of bias due to unclear allocation concealment and
by one more for imprecision because the 95% CI included both
benefit and harm.
Two studies with 752 participants used the catheter as the unit of
analysis for catheter patency duration (Pumarola 2007; Schallom
2012). We observed no clear differences between heparin and NS
groups (MD 0.40, 95% CI -0.20 to 0.99; I² = 0%; P = 0.19;
Analysis 4.2). We judged the quality of evidence to be moderate.
We downgraded the quality of evidence by one level for impreci-
sion because the 95% CI included both benefit and harm.
No studies reporting on this outcome used line access as the unit
of analysis.
Secondary outcomes
See additional Table 1.
Episodes of CVC-related sepsis and CVC-related
colonisation
Two studies (1097 participants) reported on sepsis (Goosens 2013;
Schallom 2012). Analysis showed no clear evidence of an effect
with heparin use (RR 0.74, 95% CI 0.03 to 19.54; I² = 75%; P
= 0.86; Analysis 5.1). Heterogeneity among studies was high (I²
= 75%). In Schallom 2012, four participants in the saline group
experienced episodes of CVC-related sepsis compared with none
in the heparin group (data received via personal communication
with study author). Study authors treated all four participants
using non-antibiotic-impregnated catheters. This difference was
not statistically significant (X² = 2.180; P = 0.14; Yates correction
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applied). Goosens 2013 found catheter-related bacteraemia in two
out of 404 cases (0.5%) in theNS group and in six out of 398 cases
(1.5%) in the heparin group (P = 0.18). We judged the quality
of evidence to be low. We downgraded the quality of evidence by
two levels for imprecision because the 95% CI was very wide and
included both harm and no harm.
Mortality
Three studies (1100 participants) reported on mortality (Goosens
2013; Kaneko 2004; Pumarola 2007). Results showed no evidence
of an effect (RR 0.76, 95% CI 0.44 to 1.31; I² = 0%; P = 0.33;
Analysis 5.2). Kaneko 2004 did not report deaths, Pumarola 2007
reported three deaths (two in the heparin group and one in the
NS group, without significant differences), and Goosens 2013
reported 48 deaths (28 in the NS group and 20 in the heparin
group; P = 0.255). No other included studies reported mortality.
We judged the quality of evidence to be low. We downgraded the
quality of evidence by one level for risk of bias due to unclear
allocation concealment and by one more for imprecision because
the 95% CI included both harm and no harm.
Haemorrhage from any site in the body
Four studies (1245 participants) reported on bleeding (Beigi 2014;
Goosens 2013;Kaneko2004; Schallom2012).Weobservedno ev-
idence of a difference in bleeding between heparin and NS groups
(RR 1.32, 95% CI 0.57 to 3.07; I² = 0%; P = 0.52; Analysis 5.3).
Beigi 2014 reported four and three bleeding events in heparin and
NS groups, respectively. Goosens 2013 reported no haemorrhages
in any group. Kaneko 2004 reported oozing from the exit site of
the dialysis catheter in five participants in the heparin group and
in five in the NS group with no statistically significant differences
(X² = 0.088; P = 0.799). In Schallom 2012, one participant in
the heparin group presented with bleeding versus none in the NS
group (X² = 0; P = 0.984; Yates correction). We judged the quality
of evidence to be moderate. We downgraded the quality of evi-
dence by one level for imprecision because the 95% CI included
both harm and no harm.
Heparin-induced thrombocytopaenia (HIT)
Only Kaneko 2004, Mahesh 2014, and Schallom 2012 reported
on HIT. Neither Kaneko 2004 nor Mahesh 2014 found cases of
HIT. Schallom 2012 detected two cases, both in the NS group.
Pooling data showed no clear evidence of an effect (RR 0.21,
95% CI 0.01 to 4.27; P = 0.31; Analysis 5.4). We judged the
quality of evidence to be low. Only one study detected HIT (
Schallom2012), with a finding that is counterintuitive (lowerHIT
inpatients treatedwith heparin locking).Moreover, the confidence
interval is large, and therefore uncertainty is high. In addition,
investigators removed seven participants from the heparin locked
catheter group because of concerns about bleeding or HIT.
CVC-related thrombosis
Only three studies (1527 participants) reported on the incidence
of CVC-related thrombosis (Dal Molin 2015; Goosens 2013;
Schallom 2012). Pooled results show no evidence of a difference
in effect between heparin and NS groups (RR 1.24, 95% CI 0.77
to 2.02; I² = 0%; P = 0.38; Analysis 5.5).
Schallom2012 found 10.7% venous thromboembolism in theNS
group (16 participants) and 13.1% (19 participants) in the hep-
arin group (X² = 0.419; P = 0.518), with no statistical differences
between groups. Goosens 2013 found a confirmed diagnosis of
central venous thrombosis in 13 participants (3.3%) in the hep-
arin group and in 11 participants (2.8%) in the NS group (X² =
0.060; P = 0.807), retrospectively. Dal Molin 2015 reported one
thrombosis in the heparin group.
We judged the quality of evidence to bemoderate.We downgraded
the quality of evidence by one level for imprecision because the
95% CI included both benefit and harm.
Number of additional CVC insertions
None of the included studies provided data on this outcome.
Abnormality of coagulation profile
Only Kaneko 2004 reported alterations in coagulation parame-
ters. These investigators studied activated coagulation time (ACT),
activated partial thromboplastin time (APTT), and prothrombin
time (PT). Kaneko 2004 found differences between groups for
both ACT (P < 0.001) and APTT (P = 0.001). In particular, said
parameters, except PT (P = 0.187), were higher in the heparin
group. Differences observed in the PT parameter, which was ele-
vated in the heparin group, did not reach statistical significance.
We judged the quality of evidence to be low. We downgraded the
quality of evidence by one level for risk of bias due to unclear
allocation concealment and by one more for imprecision because
the 95% CI included both harm and no harm.
Allergic reactions to heparin
None of the included studies provided data on this outcome.
Sensitivity analysis
We planned to carry out sensitivity analyses affecting main out-
comes (occlusions) for published versus unpublished studies, for
quality of studies, and for weight of studies, as well as for odds
ratio versus risk ratio.
The only study initially identified as an unpublished study was
Goosens 2013, but this studywas later published, andwe identified
no other unpublished studies. So, we cannot perform this kind of
predefined sensitivity analysis.
We found that results for occlusion in studies having poor or
unclear allocation concealment favoured heparin locking versus
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NS (RR 0.39, 95% CI 0.16 to 0.95), but this effect was lost when
studies with good allocation concealment were considered (RR
0.74, 95% CI 0.51 to 1.05; Analysis 6.1).
We explored the influence of studies contributingmost to the effect
estimate to assess whether a single study could reverse the direction
of the effect. When we considered the outcome occlusions, the
studywith the greatestweightwasGoosens 2013 (49.0%).Weper-
formed a sensitivity analysis by removing this study from the anal-
ysis and found that the direction of effect changed, now favouring
heparin locking (RR 0.52, 95% CI 0.30 to 0.91; Analysis 6.2).
We explored and calculated differences between odds ratio and
risk ratio but found them to be not significant.
We also explored effect size in occlusions and patency. Here we
standardised the results, so they were independent of the unit of
analysis. We did this because there was discussion in the review
author group about whether it was appropriate to combine studies
for which the unit of analysis was the participant with studies for
which the unit of analysis was the catheter. Overall the team con-
cluded that it was reasonable to do so because most participants
only ever have one catheter, and therefore the two approximated
to each other. However we also treated each unit of analysis as a
subgroup (Analysis 1.1). A different strategy for meta-analysing
results that are addressing the same underlying construct but mea-
suring this construct in different ways is to standardise the results
by converting them to an effect size, that is, a ’z-score’ of a standard
normal distribution. We did this in the sensitivity analysis in case
readers of the review disagreed with our pragmatic approach in
Analysis 1.1.
We calculated the effect size for occlusionswhen the unit of analysis
of the participant was considered (RR 0.84, 95% CI 0.65 to 1.08)
versus effect size when the unit of analysis of the catheter was
considered (RR 0.54, 95% CI 0.31 to 0.96). Testing for subgroup
differences showed no clear differences between the subgroups (P
= 0.17; Analysis 6.3).
In a similar way, we assessed effect on patency when the unit of
analysis was the participant (RR 0.66, 95% CI -0.66 to 1.97) and
when it was the catheter (RR 0.40, 95%CI -0.20 to 0.99). Testing
for subgroup differences showed no statistical differences between
the subgroups (P = 0.72; Analysis 6.4).
Subgroup analysis
We planned to perform subgroup analyses by type of participant,
CVC site and CVC type, and infusate-related factors. We carried
out subgroup analysis by heparin concentration used, oncology/
non-oncology patients, number of CVC lumens, and time to fol-
low-up. Data were insufficient for analysis by CVC implantation
site or CVC type subgroup. We carried out subgroup analyses by
unit of analysis and reported these results above under the relevant
outcomes.
Subgroup analysis to investigate occlusion in oncology and non-
oncology patients showed differences between groups. Occlusions
in non-oncological participants were different from those in on-
cological participants (RR 0.48, 95% CI 0.30 to 0.77; P = 0.002;
vs RR 0.91, 95% CI 0.69 to 1.19; P = 0.48; respectively), favour-
ing heparin use in non-oncological participants (test for subgroup
differences P = 0.02; Analysis 7.1).
Subgroup analysis to assess the relationship between occlusion and
the number ofCVC lumens (unit of analysis - participants) showed
no clear differences between groups: occlusions in studies using
CVCs with one lumen (RR 0.85, 95% CI 0.57 to 1.26) versus
those using CVCs with more than one lumen (RR 0.63, 95% CI
0.15 to 2.59) (test for subgroup differences P = 0.69; Analysis 7.2).
Subgroup analysis to investigate the effect of heparin concentration
on occlusion showed no clear differences between high (≥ 1000
IU/mL) and low concentrations (< 1000 IU/mL). According to
heparin concentration, high concentrations (RR 0.41, 95% CI
0.14 to 1.25) versus low concentrations (RR 0.65, 95% CI 0.31
to 1.34) showed no clear differences (test for subgroup differences
P = 0.50; Analysis 7.3).
We performed subgroup analysis to assess whether occlusions were
related to time to follow-up. When time to follow-up was less
than one month (RR 0.48, 95% CI 0.30 to 0.77), we found
differences favouring heparin. When time to follow-up was one
month or longer, we noted no clear differences (RR 0.91, 95% CI
0.69 to 1.19). Testing for subgroup differences showed differences
between the subgroups (P = 0.02; Analysis 7.4).
D I S C U S S I O N
Summary of main results
The aim of the present update was to assess the effectiveness of
intermittent locking with heparin versus normal saline (NS) in
adults with central venous catheters (CVCs) in terms of preven-
tion of occlusion and overall benefits versus harms. Central venous
catheters are frequently used to provide blood derivatives, medi-
cation, or nutritional support to patients, as well as for diagnostic
monitoring, cardiac pacing, and other procedures. However, their
use could result in thrombosis and infection and may prolong hos-
pital stay.
Very low-quality evidence suggests that in adults, intermittent
locking of CVCs with heparin may result in fewer occlusions than
intermittent locking with NS. Low-quality evidence suggests that
heparin has little or no effect on catheter patency. Although we
did not detect differences in safety, the trials that were combined
are not sufficiently powered to detect rare adverse events, such as
heparin-induced thrombocytopaenia (HIT). Lack of an effect of
heparin concentration and the suggestion of publication bias as
demonstrated by the funnel plot mean that these results should
be interpreted cautiously. These findings on efficacy (occlusion
and patency) could be related to the types of participants included
(more benefit for non-oncological patients) and to the quality of
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trials. The quality of the evidence ranged from very low to mod-
erate.
Overall completeness and applicability of
evidence
Review authors examined all addressed outcomes. Statistical het-
erogeneity was low (I² = 0) for the main outcomes of efficacy (oc-
clusion and patency) and safety (bleeding, thrombosis, and mor-
tality), despite inclusion of participants with very different condi-
tions (critical, with onco-haematological malignancies, or under
haemodialysis), treated with a very wide range of heparin con-
centrations ranging from 30 IU/mL to 2500 IU/mL. Only sep-
sis showed significant statistical heterogeneity (I² = 75%), which
could be explained by the different clinical conditions of partici-
pants in the two studies reporting sepsis.
Our results are consistent with those of a retrospective cohort study
by Jonker 2010, which detected increased use of alteplase to clean
catheters flushed with NS compared with catheters locked with
heparin. However, these results may be biased by the indirectness
of outcomes.
It is interesting to consider also the use of systemic anticoagulants
among different studies. In Pumarola 2007 and Goosens 2013,
use of any anticoagulation was a criterion of exclusion; although
Bowers 2008, Kaneko 2004, Rabe 2002, and Schallom 2012 pro-
vided no data on permitted use of systemic anticoagulation in ev-
ery participant (Kaneko 2004), or in only some participants (Rabe
2002; Schallom 2012), differences were found to be not signif-
icant. Moreover, Dal Molin 2015 excluded patients with intol-
erance to heparin, and Heidari 2015 excluded patients with risk
of bleeding. However, exclusion of Pumarola 2007 and Goosens
2013 - two studies that used the exclusion criterion of use of an-
ticoagulants - resulted in no change in findings of the sensitivity
analysis.
Length of follow-up for safety in this review could be too short
to reveal relevant adverse events. Only Dal Molin 2015 (231
days) and Goosens 2013 (180 days) provided long-term follow-
up, whereas Beigi 2014, Lyons 2014, Mahesh 2014, Pumarola
2007, Rabe 2002, and Schallom 2012 studied participants for a
shorter time; Heidari 2015 had medium-term follow-up (around
20 days); Bowers 2008 and Kaneko 2004 studied participants for a
period ranging from 40 to 50 days. Consequently, the potential for
higher incidence with long-term follow-up cannot be discarded.
Given that CVCs could be placed for several months according to
the needs of patients, adverse events may be more relevant than
those described in the present systematic review. None of the 11
included trials were planned to study adverse events. In summary,
it cannot be ruled out that adverse events may occur with longer
exposure or larger numbers of participants.
Despite results suggesting no differences in safety, it is probable
that a high proportion of patients could be at increased risk with
heparin use. This increased risk of adverse events due to heparin
lockingmay be especially relevant among patients with liver or kid-
ney failure and those with recent surgery (especially of the brain,
eye, or spine), spinal anaesthesia, or recent injury. Also patients
who have a history of heart problems, high blood pressure, men-
strual problems, bleeding problems, or a history of ulcers or other
stomach problems, or who are taking drugs such as non-steroidal
anti-inflammatory drugs or antiplatelet agents,may have increased
risk of bleeding. Adverse events may be reduced by flushes with
NS.
Heparin-induced thrombocytopaenia (HIT) is an adverse event
that may be life-threatening. It is more common after intraoper-
ative or perioperative administration of heparin. Its incidence is
reported at between 0.1% and 5%. Risk factors for HIT include
type of heparin used (greater risk with unfractionated heparin),
duration of exposure, patient setting, and patient gender (1.5 to 2
times higher among women) (Battistelli 2010). In general, higher
doses of heparin result in greater risk of HIT. However, lower hep-
arin doses used to flush catheters have occasionally been associated
with HIT (McNulty 2005). In the present systematic review, HIT
was not reported in the heparin groups, and only two cases were
reported in the NS groups (Schallom 2012), suggesting altogether
an undiagnosed adverse event. Nevertheless, routine use of NS
instead of heparin may reduce HIT.
Quality of the evidence
We have presented the main results in Summary of findings for
the main comparison. The quality of evidence ranged from very
low to moderate.
The quality of evidence for the main outcome (all occlusions of
CVC) was very low. We downgraded the quality of evidence by
one level for risk of bias due to unclear allocation concealment,
by another level for imprecision (95% confidence interval (CI)
included both no harm and harm), and by an additional level
for risk of bias due to suspected publication bias (see funnel plot;
Figure 1). Although the common rule is not to create a funnel
plot for fewer than 10 studies, we created a funnel plot because
the included studies described different effects and different sizes.
Although other possible sources of asymmetry can be addressed
(selection bias, poor method, artefacts, or chance), we cannot dis-
card publication bias.
Despite the fact that some trials were not blinded, we judged that
lack of blinding was not important for this outcome.
We judged the quality of evidence for duration of overall catheter
patency as low. We downgraded by one level for risk of bias due
to unclear allocation concealment and by another level for impre-
cision.
We judged the quality of evidence for CVC-related sepsis/coloni-
sation to be low. We downgraded the quality of evidence by two
levels for imprecision because the 95% CI included both no harm
and harm, the 95% CI was very wide, and the total number of
events was less than 400.
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We judged the quality of evidence for mortality and abnormality
of coagulation profile to be low. We downgraded the quality of
evidence by one level for risk of bias due to unclear allocation
concealment and by one more level for imprecision because the
95% CI included both no harm and harm.
We judged the quality of evidence for haemorrhage from any site
and for heparin-induced thrombocytopaenia to be low. We down-
graded the quality of evidence by one level for imprecision be-
cause the 95% CI included both no harm and harm. Moreover
the finding is counterintuitive (lower HIT among patients treated
with heparin locking).
We did not include the secondary outcomes CVC-related throm-
bosis and abnormality of the coagulation profile in Summary of
findings for the main comparison. We judged the quality of ev-
idence for CVC-related thrombosis to be moderate. We down-
graded the quality of evidence by one level for imprecision because
the 95% CI included both no harm and harm. We judged the
quality of evidence for abnormality of the coagulation profile to be
low. We downgraded the quality of evidence by one level for risk
of bias due to unclear allocation concealment and by one more
for imprecision because the 95% CI included both no harm and
harm.
In summary, risk of bias for unclear allocation concealment and
imprecision were the items that downgraded the quality of evi-
dence for most outcomes, and risk of publication bias could be
added for the outcome “all occlusions”.
Potential biases in the review process
Review authors carried out study selection and data extraction in
a duplicate manner. We published a protocol for this systematic
review (López-Briz 2010). None of the authors of this review up-
date was involved in any of the included or excluded studies. We
selected a priori all outcomes analysed. We contacted trial authors
and retrieved additional information. Hence the probability of
publication bias among studies included in this systematic review
is low. However, we could not discard bias from non-published
studies after we assessed the funnel plot for publication bias (Figure
1).
For the unit of analysis of participant or catheter, heparin showed
a small benefit. We concluded that it was reasonable to pool both
units of analysis because most participants only ever have one
catheter, and therefore the two approximated to each other. This
was an “a posteriori” decision, and it must be kept in mind when
review results are interpreted.
Agreements and disagreements with other
studies or reviews
Other systematic reviews focussed on heparin use in CVCs have
used different inclusion and/or exclusion criteria from those of this
review. Randolph 1998b reviewed randomised controlled trials in
adult and paediatric participants in whom heparin was infused
continuously through the catheter, administered subcutaneously
(SC), or bonded to the catheter. They found a trend toward a re-
duction in catheter thrombus and a significant reduction (57%)
in venous thrombosis. Statistical heterogeneity was not significant
in both cases. Heparin dosage ranged from SC 5000 IU every 12
hours to 1 IU/mL in continuous perfusion added to total par-
enteral nutrition.
Klerk 2003 also reviewed studies with adult and paediatric par-
ticipants with CVCs in whom heparin flushes or antithrombotic
agents were administered in prophylactic or therapeutic doses.
This review concluded that heparin added to parenteral nutrition
did not significantly decrease the risk of catheter-related thrombo-
sis. However, this review cannot be compared with the present one
because it differs in the design of included studies (randomised
controlled trials and prospective cohort studies) and in the inter-
vention provided (systemic heparin).
A previous systematic review conducted by some of the authors of
this Cochrane review found and included only two studies, one of
which included paediatric participants (López-Briz 2005). Results
show no differences between heparin and NS locking.
Mitchell 2009 conducted a systematic review focussed on adult
participants with CVCs or peripherally inserted central catheters
(PICCs) comparing heparin locking, continuous heparin perfu-
sion, NS locking, urokinase locking, and heparin-bonded catheter
versus any other intervention. The review authors concluded that
“there is insufficient evidence on which to find that flushing
catheters with heparin are more effective than flushing with saline
solution”.
In paediatric participants, Shah 2008 found that continuous hep-
arin infusion reduced the risk of catheter occlusion with no statis-
tically significant differences in the duration of catheter patency.
However, the review authors could not provide recommendations
for heparin use in neonates with PICCs. These review authors de-
tected high clinical heterogeneity and high heterogeneity in treat-
ment effect.
Guidelines have led to a wide variety of locking protocols, with
many different types of locking solutions, volumes, locking fre-
quencies, and heparin concentrations because these guidelines are
based mainly on manufacturers’ recommendations - not on pub-
lished evidence (Mitchell 2009; Sona 2012). The Infusion Ther-
apy Standards of Practice (INS 2016) “lists Heparin 10 units per
mL or preservative free 0.9% sodium chloride to lock CVADs.
This lower strength of heparin is recommended in an effort to
reduce the occurrence of heparin-induced thrombocytopenia and
thrombosis (HITT)”, and Sousa 2016 stated that “Intermittent
flushing with heparin is a standard practice in the maintenance of
CVC patency. However, when compared with 0.9% normal saline
flushing, no differences in thrombosis rates were found”.
Lately, three systematic reviews stated no differences. Dal Molin
2014 performed a network meta-analysis and concluded: “There
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is no evidence of a different effectiveness between heparin flushing
and normal saline or other solutions in reducing catheter occlu-
sions”. Zhong 2017 concluded that heparin locking is not superior
to saline in the maintenance of CVC lumen catheters. In a post
hoc analysis, these review authors suggested that heparin could be
effective when used with follow-up of less than one month. We
found the same data but noted lack of plausibility only about this
time-limited effect. Bradford 2015 and Bradford 2016 carried out
a similar systematic review in paediatric patients and concluded:
“It remains unclear whether heparin is necessary for CVCmainte-
nance”. Nevertheless, review authors provided conclusions about
occlusions with only two trials, one of which, Goosens 2013, in-
cluded only 3.5% of patients under 18 years (26 participants).
Summarising all these systematic reviews revealed a protective ef-
fect for occlusions with heparin, but without statistical signifi-
cance. Our review update includes more trials and more partici-
pants, and our results reached statistical significance.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Very low-quality evidence suggests that in adults, central venous
catheters that are intermittently lockedwith heparin result in fewer
occlusions than catheters locked with normal saline (NS). Low-
quality evidence suggests that heparin may have little or no effect
on duration of catheter patency. We found no evidence of an in-
creased effect with increasing concentrations of heparin and no
evidence of differences in the relative safety of the two methods
of intermittent locking when central venous catheter (CVC)-re-
lated sepsis, mortality, or haemorrhage was considered, although
the trials combined are not powered to detect rare adverse events
such as heparin-induced thrombocytopaenia. To sum up, we are
uncertain about the effects of heparin compared toNS, and review
findings should be interpreted with caution.
Implications for research
Better designed large-scale randomised controlled trials are needed
to definitively establish or rule out a net benefit of locking with
heparin versus 0.9% NaCl (normal saline); these trials should also
explore effectiveness in different patient groups, such as patients
under haemodialysis or those with onco-haematological malig-
nancies. Trials should report the outcome using both the partici-
pant and the catheter as units of analysis to allow evidence to be
combined more consistently. Occlusions and adverse events must
be the focus of future trials, and we suggest at least one month
of follow-up. In addition, assessment by type of line (i.e. dialy-
sis/apheresis vs peripherally inserted central catheter (PICC) or vs
other) is important. Addressing the question of harm from rare
events requires high-quality prospective cohort studies with suf-
ficient duration of follow-up. Decision analytical modelling in-
corporating the costs of heparin and saline and the probabilities
and costs of alteplase use and catheter replacement may also help
establish the thresholds required to make one or another method
the most appropriate and efficient choice.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beigi 2014
Methods RCT
Participants 100 adult patients from Iran with chronic kidney disease
Interventions Locking with heparin (1000 IU) vs with 0.9% saline
Outcomes Manoeuvre needed to maintain catheter patency; catheter thrombosis; bleeding; PTT
Notes Follow-up: 24 hours
Unit of randomisation: the participant
Source of support: Isfahan University of Medical Sciences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation numbers
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded to outcomes but outcome measurement not likely
to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three participants in the heparin group and 1 in the 0.9%NaCl
group withdrew
Selective reporting (reporting bias) Unclear risk We sent a letter to study authors regarding the protocol, but we
received no response
Other bias Unclear risk Only 24 hours of follow-up
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Bowers 2008
Methods RCT open-label
Participants 102 participants with single-lumen PICCs with luer-activated devices, from USA
Interventions Locking with:
• Heparin 100 IU/mL locking (3 mL)
• 0.9% sodium chloride locking (10 mL)
Outcomes Occlusion of PICCs, average duration of use of catheter (in days)
Notes Follow-up until the first of the following: event (occlusion) or discharge
No data on use of systemic anticoagulation, as stated by study authors
Unit of randomisation: the participant
Source of support: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A random block design with concealment was used”
Allocation concealment (selection bias) Unclear risk Information insufficient to permit judgement. Method of con-
cealment not described or not described in sufficient detail to
allow a definitive judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial, but the outcome is not likely to be influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment but outcome measurement
not likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers across intervention
groups, with similar reasons for missing data across groups
Selective reporting (reporting bias) Unclear risk Study protocol is not available, but it is clear that published
reports include all expected outcomes, including those that were
prespecified
Other bias Low risk Study appears to be free of other sources of bias
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Dal Molin 2015
Methods Multi-centre open-label RCT conducted in 14 Italian oncology clinics
Participants 430 adult patients with cancer with a new TIVAD from Italy
Interventions 5 mL (50 IU) of normal saline via positive-pressure technique vs “heparin” (the device
was flushed as in the normal saline group, then was locked with 5 mL of heparin solution
(50 UI/mL) using positive-pressure technique)
Outcomes Main outcome: port failure for lumen occlusion
Secondary outcomes: catheter-related infections, thrombosis, extravasation
Notes Patients with leukaemia or known intolerance to heparin were excluded, as were those
whose device had some complications after insertion or who were planning to start
parenteral nutrition with lipid. Patients with implanted TIVAD requiring TPN during
the course of the study were kept off the study because of increased risk of occlusion
due to TPN. Median follow-up was 231.8 days in the saline group and 251.8 day in the
heparin group
Unit of randomisation: the participant
Source of support: Fondo Edo Tempia of Biella
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A random allocation sequence was
created using a computerized procedure
on-line”
Allocation concealment (selection bias) Low risk Allocation was determined after the nurse/
doctor entered some patient and device
data into the web page of the study. The
goal of the procedure was to ensure that
the clinician was not informed a priori if
patient had been assigned to normal saline
group or heparin group. Therefore alloca-
tion sequence was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label, but outcome measurement
not likely to be influenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label, but outcome measurement
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% of withdrawals in 0.9% NaCl group
and 2.5% in heparin group with no details
provided
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Dal Molin 2015 (Continued)
Selective reporting (reporting bias) Low risk Eudract number: 2009-013620-22. All
outcomes reported in the protocol were
stated in the paper
Other bias Unclear risk Not enough information to permit judge-
ment of other bias
Goosens 2013
Methods RCT open-label non-inferiority
Participants 802 participants older than 1 year with an onco-haematological malignancy, from Bel-
gium
Interventions Locking with:
• 10 mL 0.9% NaCl and after 3 mL heparin (100 IU/mL)
• 10 mL 0.9% NaCl
Outcomes Primary outcome: withdrawal occlusion at access (i.e. inability to aspirate blood while
injection is easy)
Secondary outcomes: catheter-related bacteraemia within 180 days, duration of catheter
Notes Follow-up: 180 days
Following contact with trialists, we obtained additional raw data, which we used in the
analysis
Use of heparin IV was an exclusion criterion
Main unit of randomisation was the number of catheters accessed, but Goosens provided
additional information about occlusions per participant
Source of support: partially funded by Leuvens Kankerinstituut and by B Braun Belgium
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number generation
Allocation concealment (selection bias) Low risk Allocation concealment by means of sequentially
numbered participant cards, stored in a separate room
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded, but the outcome is categorical (blood
aspiration possible or not) and is not likely to be in-
fluenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded, but the outcome is categorical (blood
aspiration possible or not) and is not likely to be in-
fluenced by lack of blinding
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Goosens 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reporting of attrition/exclusions insufficient to per-
mit judgement: no information on number of
catheters losing patency in each group
Selective reporting (reporting bias) Low risk NCT00994136: all outcomes available
Other bias Unclear risk No separate analyses for children (3.5%) and adults.
Not enough information to permit judgement of
other bias
Heidari 2015
Methods RCT double-blinded
Participants 84 patients from Iran in ICU
Interventions 3 mL heparin saline solution (10 IU/mL) locking vs 0.9% NaCl locking
Outcomes CVC patency
Notes Follow-up: 21 days
Exclusion criteria: risk of bleeding, receiving blood products and TPN during study,
increase in body temperature greater than 37.7°C
Unit of randomisation: the participant
Source of support: Mazandaran University of Medical Sciences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers generated by Excel software’s Rand Between
Function
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were unaware of the method used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In this study, the ward nurse prepared heparin and normal saline
solutions, and the researcher was unaware of the content of
serum
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were followed up
Selective reporting (reporting bias) Unclear risk We sent a letter to study authors regarding the protocol, but we
received no response
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Heidari 2015 (Continued)
Other bias Unclear risk Not enough information to permit judgement of other bias
Kaneko 2004
Methods RCT open-label
Participants 48 participants under haemodialysis with double-lumen CVC, from Japan
Interventions Locking with:
• 20 mL 0.9% NaCl + 2 mL heparin 1000 IU/mL lock
• 20 mL 0.9% NaCl
Outcomes Thrombotic occlusion, catheter survival, catheter patency time, haematological and co-
agulation markers, safety
Notes LMWH (dalteparin, parnaparin, or reviparin) at 8 IU/kg was used during each
haemodialysis session
Follow-up was not clearly reported, but average period of catheter patency until removal
or occlusion was almost the same mean 17.3 days in the saline group and 18.1 days in
the heparin group
Unit of randomisation: the participant
Source of support: provided in part by Fresenius Medical Care Dialysis Foundation and
by Unitika Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information about sequence generation process insufficient to
permit judgement
Allocation concealment (selection bias) Unclear risk Information insufficient to permit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment, but outcome measurement
not likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals (9/22 = 40%) in heparin group and saline group
(8/26 = 30%). No data regarding reasons for withdrawals
Selective reporting (reporting bias) Unclear risk Study protocol is not available, but it is clear that published
reports include all expected outcomes, including those that were
prespecified
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Kaneko 2004 (Continued)
Other bias Unclear risk Not enough information to permit judgement of other bias
Lyons 2014
Methods RCT single-blinded
Participants 90 home care patients, from USA. Participants were recruited from the home infusion
service’s affiliated university medical centre at the time of their discharge to home with
PICCs placed
Interventions 0.9% NaCl 10 mL vs low doses of heparin (10 IU/mL) 5 mL vs high doses of heparin
(300 IU/mL) 3 mL
Outcomes Quote: “Development of patency-related complications and other significant issues such
as sluggishness, occlusion, missed medication doses, catheter replacement, additional
nursing visits, and the use of alteplase”
Notes Follow-up according to “Subjects’ length of time in the study was determined by their
prescribed therapy length and/or the study’s end date”
Mean follow-up: 23 days per participant
Unit of randomisation: the participant
Source of support: Gardner Foundation of the INS and Alpha Nu Chapter of Sigma
Theta Tau International
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “were randomly assigned”
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed envelope method. Prin-
cipal investigator was blind to which study group a participant
was assigned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blinded without more details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Single-blinded without more details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Without withdrawals
Selective reporting (reporting bias) Low risk We contacted the study author, who sent the study protocol to
us
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Lyons 2014 (Continued)
Other bias Low risk Study appears to be free of other sources of bias
Mahesh 2014
Methods RCT
Participants 100 participants from the Respiratory Intensive Care Unit with CVC with triple lumen,
from India
Interventions Heparin (3 mL, 10 IU/mL) or 0.9% NaCl (10 mL) flushes every 8 hours
Outcomes Primary outcome: lumen non-patency, defined as inability to both withdraw blood and
flush through a lumen. The conclusion of lumen non-patency was arrived at only after
the following interventions:
• If the lumen could not be flushed, the participant was repositioned and the flush
re-attempted
• If still unable to flush, the syringe was changed and the flush re-attempted
Secondary outcome: heparin-induced thrombocytopaenia (HIT), assessed by daily
platelet count, starting on day 4 from the time of giving heparin flushes for all partici-
pants in Group H
Notes Exclusion criteria: known heparin allergy, diagnosis of HIT, bleeding risk identified by
attending physician, age < 18 years or > 58 years, requiring prolonged ICU stay with
ailments such as terminal illness, severe septicaemia, MODS, etc
Follow-up: average 1 week
Unit of randomisation: the participant
Source of support: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Without details
Allocation concealment (selection bias) Unclear risk Without details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial is not blinded, but outcome measurement is not likely to
be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial is not blinded, but outcome measurement is not likely to
be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Without withdrawals
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Mahesh 2014 (Continued)
Selective reporting (reporting bias) Unclear risk The protocol is not available. Moreover this is not indexed in
PubMed or CENTRAL
Other bias Unclear risk Not detected
Pumarola 2007
Methods RCT blinded
Participants 250 patients in ICU with 3-lumen CVC, from Spain
Interventions Locking with:
• 5 mL 0.9% NaCl
• 5 mL heparin 100 IU/mL
Outcomes Catheter patency at 24 hours, at 72 hours, and at discharge from ICU (mean 4.74, SD
5)
Notes Two-phase trial: in the first phase, 2 different dosages of heparin were compared; in the
second phase, heparin was compared with 0.9% NaCl in 95 CVCs
Follow-up until first of the following: event (occlusion) or discharge
Exclusion criterion: systemic anticoagulant use
Unit of randomisation: the catheter
Source of support: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation computer generated (software Aleator)
Allocation concealment (selection bias) Unclear risk Information was insufficient to permit judgement. Method of
concealment is not described or is not described in sufficient
detail to allow a definitive judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial, but the outcome is not likely to be influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment, but outcome measurement
not likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing outcome data balanced in numbers across intervention
groups, with similar reasons for missing data across groups, but
a very high rate of withdrawals: heparin 87/125 and saline 68/
125
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Pumarola 2007 (Continued)
Selective reporting (reporting bias) Unclear risk Study protocol is not available, but it is clear that published
reports include all expected outcomes, including those that were
prespecified
Other bias High risk Study may be underpowered: only 38 and 57 participants per
group were analysed, but predetermined sample size was 125
participants per group. Study was stopped early for 74 partici-
pants in the heparin group and for 52 participants in the 0.9%
NaCl group
Rabe 2002
Methods RCT open-label
Participants 91 ICU patients with 99 implanted 3-lumen CVCs, from Germany
Interventions Catheter lock with 0.5 mL of:
• Heparin 5000 IU/mL
• 0.9% NaCl
• Vitamin C 200 mg/mL
Outcomes Catheter patency (tested every 2 days)
Notes Follow-up: 20 days
Prophylactic or therapeutic anticoagulation used in the 3 groups but with non-significant
differences
Unit of randomisation: the catheter
Source of support: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list prepared by study authors using a random
number generator
Allocation concealment (selection bias) Unclear risk Information insufficient to permit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial, but the outcome is not likely to be influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment, but outcome measurement
is not likely to be influenced by lack of blinding
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Rabe 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reporting of attrition/exclusions insufficient to permit judge-
ment: no information about number of catheters losing patency
in each group
Selective reporting (reporting bias) Unclear risk Study protocol is not available, but it is clear that published
reports include all expected outcomes, including those that were
prespecified
Other bias Unclear risk Not enough information to permit judgement of other bias
Schallom 2012
Methods RCT open-label
Participants 295 patients (326 catheters, 709 lumens) from medical or surgical ICU in whom a 3-
or 4-lumen CVC was inserted, from USA
Interventions Flushes every 8 hours with:
• 3 mL heparin 10 IU/mL
• 10 mL 0.9% NaCl
Outcomes Rate of lumennon-patency, blood loss return, flush failure, rate of catheter-related blood-
stream infection, HIT
Notes Follow-up: 22 days
Prophylactic or therapeutic anticoagulation was used in both groups with non-significant
differences
Unit of randomisation: the catheter
Source of support: no financial support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Investigators used a computerised random number generator in
MS Excel
Allocation concealment (selection bias) Low risk Quote: “The allocation sequence was concealed until the card
was retrieved upon obtaining patient consent”
Follow-up: 1-27 days
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment, but outcome measurement
not likely to be influenced by lack of blinding
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Schallom 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1/165 in saline group and 7/162 in heparin group with-
drew
Selective reporting (reporting bias) Unclear risk Study protocol is not available, but it is clear that published
reports include all expected outcomes, including those that were
prespecified
Other bias Unclear risk Not enough information to permit judgement of other bias
CVC: central venous catheter.
HIT: heparin-induced thrombocytopaenia.
ICU: intensive care unit.
LMWH: low molecular weight heparin.
MODS: multi-organ dysfunction syndrome.
PICCs: peripherally inserted central catheters.
PTT: partial thromboplastin time.
RCT: randomised controlled trial.
SD: standard deviation.
TIVAD: totally implantable vascular access device.
TPN: total parenteral nutrition.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AACCN 1993 Arterial catheters were used
Abdelkefi 2004 Interventions do not fulfil inclusion criteria (continuous infusion)
Abdelkefi 2005 Interventions do not fulfil inclusion criteria (continuous infusion)
Abdelkefi 2005a Interventions do not fulfil inclusion criteria (heparin-coated catheters)
Abdelkefi 2007 Interventions do not fulfil inclusion criteria (heparin-bonded catheter + normal saline vs non-
coated catheter + continuous infusion heparin)
Abdelkefi 2008 Interventions do not fulfil inclusion criteria (impregnated catheters)
Agnelli 2009 Interventions do not fulfil inclusion criteria (systemic nadroparin)
Akyuz 2010 Comparison does not fulfil inclusion criteria (heparin vs taurolidine + citrate)
Alexander 2010 Peripheral catheters were used
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(Continued)
Ankola 1993 Arterial catheters were used; interventions do not fulfil inclusion criteria
Anton 2009 Intervention and participants do not fulfil inclusion criteria (children, heparin-bonded catheters)
Appelgren 1996 Interventions do not fulfil inclusion criteria (heparin-bonded catheters)
Aquino 2002 Interventions do not fulfil inclusion criteria (urokinase flushes)
Araujo 2008 Interventions do not fulfil inclusion criteria (catheter comparison)
Arnts 2011 Peripheral catheters were used. Participants do not fulfil inclusion criteria (neonates)
Arrants 1999 Interventions do not fulfil inclusion criteria (saline lock only)
Ashton 1990 Peripheral catheters were used
Aslam 2011 Comparisons do not fulfil inclusion criteria (heparin or citrate vs heparin + tigecycline + N-
acetylcysteine)
Bailey 1979 Interventions do not fulfil inclusion criteria (continuous perfusion of heparin)
Balduini 2010 Peripheral catheters were used
Barrett 1990 Interventions do not fulfil inclusion criteria (peripheral catheters)
Barriga 1997 Interventions do not fulfil inclusion criteria (heparin with or without vancomycin)
Bennegard 1982 Interventions do not fulfil inclusion criteria (heparin-coated vs non-coated catheters)
Bertolino 2012 Peripheral catheters were used
Betjes 2004 Comparison does not fulfil inclusion criteria (heparin vs citrate-taurolidine)
Bisseling 2010 Comparison does not fulfil inclusion criteria (heparin vs taurolidine)
Bleyer 2005 Comparison interventions do not fulfil inclusion criteria (heparin vs minocycline + EDTA)
Bolgiano 1990 Arterial catheters were used
Branger 2011 Interventions do not fulfil inclusion criteria (arteriovenous fistula vs tunnelled jugular vein catheter)
Branson 1993 Comparison interventions do not fulfil inclusion criteria (heparin vs sodium citrate)
Brismar 1982 Interventions do not fulfil inclusion criteria (systemic heparin)
Broom 2009 Comparison interventions do not fulfil inclusion criteria (heparin vs ethanol)
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Broom 2012 Comparison interventions do not fulfil inclusion criteria (heparin vs ethanol)
Butt 1987 Arterial catheters were used
Buturovic 1998 Comparison interventions do not fulfil inclusion criteria (heparin vs citrate vs polygeline)
Campos 2011 Comparison interventions do not fulfil inclusion criteria (heparin vs ethanol)
Cardinal 2000 Comparisons do not fulfil inclusion criteria (heparin vs sodium citrate)
Carrasco 2004 Interventions do not fulfil inclusion criteria (heparin-coated catheter)
Carratala 1999 Interventions do not fulfil inclusion criteria (heparin vs heparin + vancomycin)
Casale 2009 Comparisons do not fulfil inclusion criteria (comparison of 2 heparin concentrations)
Catorze 2011 Arterial catheters were used
Catton 2006 Peripheral catheters were used
Chen 2014 Comparisons do not fulfil inclusion criteria (heparin vs NaCl 10%)
Cheronis 2013 Comparisons do not fulfil inclusion criteria (heparin vs trimethoprim + EDTA + ethanol)
Chu 2009 Comparisons do not fulfil inclusion criteria (heparin vs heparin + gentamicin)
Clifton 1991 Interventions do not fulfil inclusion criteria (heparin continuous flush)
Coli 2006 Interventions do not fulfil inclusion criteria (oral anticoagulant drugs)
Conte 2003 Interventions do not fulfil inclusion criteria (systemic low molecular weight heparin)
Coplon 2007 Comparisons do not fulfil inclusion criteria (heparin vs gentamicin + citrate)
Corbett 2013 Comparisons do not fulfil inclusion criteria (heparin vs taurolidine + heparin + citrate)
Cortes 2006 Comparisons do not fulfil inclusion criteria (heparin vs minocycline + EDTA)
Daniell 1973 Interventions do not fulfil inclusion criteria (warfarin vs low molecular weight heparin)
Davanipur 2011 Comparison does not fulfil inclusion criteria (heparin vs cloxacillin + heparin)
De Cicco 2009 Interventions do not fulfil inclusion criteria (acenocoumarin vs dalteparin vs no treatment)
de la Torre 2012 Peripheral catheters were used
del Cotillo 2008 Interventions do not fulfil inclusion criteria (arterial catheters)
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del Pozo 2012 Interventions do not fulfil inclusion criteria (comparison of antibiotic concentrations)
Dogra 2002 Comparison interventions do not fulfil inclusion criteria (heparin vs gentamicin + citrate)
Donham 1987 Peripheral catheters were used
Duncan 2005 Comparison interventions do not fulfil inclusion criteria (heparin vs citrate)
Duncan 2010 Comparisons do not fulfil inclusion criteria (heparin vs taurolidine)
Dunser 2005 Interventions do not fulfil inclusion criteria (coated vs non-coated catheters)
Eloy 1987 Interventions do not fulfil inclusion criteria (catheter comparison)
Epperson 1984 Interventions do not fulfil inclusion criteria (peripheral catheters)
Garay Rubio 2011 Peripheral catheters were used
Garrelts 1989 Peripheral catheters were used
Glaspy 2000 Interventions do not fulfil inclusion criteria (systemic dalteparin)
Goh 2011 Interventions do not fulfil inclusion criteria (IV continuous heparin administration)
Goode 1993 Peripheral catheters were used
Griffin 2005 Interventions do not fulfil inclusion criteria (papaverine)
Grosso 1989 Interventions do not fulfil inclusion criteria (calcium heparin)
Gyr 1995 Interventions do not fulfil inclusion criteria (peripheral catheters)
Hall 2006 Interventions do not fulfil inclusion criteria (continuous flush)
Hamilton 1988 Peripheral catheters were used
Han 2016 Interventions do not fulfil inclusion criteria (low vs high doses of heparin)
Harter 2002 Interventions do not fulfil inclusion criteria (coated vs non-coated catheters)
Haynes 2002 Interventions do not fulfil inclusion criteria (SC device)
Hemmelgarn 2011 Comparison interventions do not fulfil inclusion criteria (heparin vs alteplase)
Hendrickx 2001 Comparison interventions do not fulfil inclusion criteria (citrate vs heparin)
Heng 2011 Interventions do not fulfil inclusion criteria (ethanol lock)
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HGU Gregorio Marañón 2010 Comparisons do not fulfil inclusion criteria (heparin vs ethanol)
Hoffer 1999 Interventions do not fulfil inclusion criteria (valved vs non-valved catheters)
Horne 1995 Comparison interventions do not fulfil inclusion criteria (heparin vs lepirudin)
Hryszko 2013 Comparisons do not fulfil inclusion criteria (comparison of 2 heparin concentrations)
Hu 2011 Comparisons do not fulfil inclusion criteria (comparison of 2 heparin concentrations)
Imamovic 2009 Comparisons do not fulfil inclusion criteria (heparin vs citrate)
Ishii 2013 Interventions do not fulfil inclusion criteria (heparin continuous administration)
Israel Ministry of Health Comparisons do not fulfil inclusion criteria (heparin vs taurolidine)
Jasinsky 2007 Interventions do not fulfil inclusion criteria (antireflux device)
Jeppesen 2013 Comparisons do not fulfil inclusion criteria (heparin vs taurolidine)
Johnson 2002 Interventions do not fulfil inclusion criteria (mupirocin)
Jonkers 2012 Comparison interventions do not fulfil inclusion criteria (heparin vs taurolidine)
Jowett 1986 Peripheral catheters were used
Kankanala 2012 Comparison does not fulfil inclusion criteria (heparin vs citrate)
Karthaus 2006 Interventions do not fulfil inclusion criteria (systemic dalteparin)
Kokenge 2010 Comparison does not fulfil inclusion criteria (heparin vs citrate)
Kovacs 2005 Interventions do not fulfil inclusion criteria (systemic dalteparin)
Kudsk 1985 Interventions do not fulfil inclusion criteria (heparin administered in continuous perfusion)
Kulkarni 1994 Interventions do not fulfil inclusion criteria (continuous flush)
Lacasaña Bellmunt 2006 Peripheral catheters were used
Lavau-Denes 2013 Interventions do not fulfil inclusion criteria (warfarin vs low molecular weight heparin)
Le 2003 Interventions do not fulfil inclusion criteria (dressings)
Leslie 1996 Comparisons do not fulfil inclusion criteria (comparison of 2 heparin concentrations)
Liang 1998 Peripheral catheters were used
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Liang 2015 Interventions do not fulfil inclusion criteria (2 heparin doses were compared)
Liao 2002 Peripheral catheters were used
Lindblad 1994 Interventions do not fulfil inclusion criteria (systemic heparin)
Lok 2007 Comparison interventions do not fulfil inclusion criteria (heparin vs sodium citrate)
Long 2006 Interventions do not fulfil inclusion criteria (heparin-bonded catheters)
Lustig 2011 Comparisons do not fulfil inclusion criteria (heparin vs citrate + ethanol + methylene blue)
Macrae 2008 Comparison does not fulfil inclusion criteria (heparin vs citrate)
Maki 2011 Comparison interventions do not fulfil inclusion criteria (heparin vs sodium citrate + methylene
blue + methylparaben + propylparaben)
Malo 2010 Comparison interventions do not fulfil inclusion criteria (heparin vs tinzaparin)
Marin 2000 Interventions do not fulfil inclusion criteria (heparin-bonded catheters)
McIntyre 2004 Comparison interventions do not fulfil inclusion criteria (heparin vs heparin + gentamicin)
Meier 2011 Interventions do not fulfil inclusion criteria (catheter comparison)
Meyer 1995 Interventions do not fulfil inclusion criteria (peripheral catheters)
Mismetti 2003 Interventions do not fulfil inclusion criteria (systemic dalteparin)
Monreal 1996 Interventions do not fulfil inclusion criteria (systemic nadroparin)
Moran 2012 Comparison interventions do not fulfil inclusion criteria (gentamicin + citrate vs heparin)
Mortazavi 2011 Comparison interventions do not fulfil inclusion criteria (heparin vs heparin + cefotaxime)
Mudge 1998 Interventions do not fulfil inclusion criteria (peripheral catheters)
Na 2012 Arterial catheters were used
NCT03114722 Comparison does not fulfil inclusion criteria (heparin vs citrate)
Niers 2007 Interventions do not fulfil inclusion criteria (systemic nadroparin)
Niesen 2003 Interventions do not fulfil inclusion criteria (peripheral catheters)
Nieto-Rodriguez 1992 Peripheral catheters were used
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NIH Clinical Centers 2002 Comparisons do not fulfil inclusion criteria (heparin vs lepirudin)
Nori 2006 Comparison does not fulfil inclusion criteria (gentamicin vs minocycline)
Oguzhan 2012 Interventions do not fulfil inclusion criteria (heparin + NaCl 26% vs heparin)
Oran 2008 Comparison interventions do not fulfil inclusion criteria (heparin lock 3 times a week vs heparin
lock 6 times a week)
Periard 2008 Interventions do not fulfil inclusion criteria (catheter comparison)
Pervez 2002 Comparison interventions do not fulfil inclusion criteria (heparin vs sodium citrate + gentamicin)
Phulara 2018 Peripheral catheters were used
Pouw 1995 Interventions do not fulfil inclusion criteria (systemic heparin)
Power 2009 Comparison interventions do not fulfil inclusion criteria (heparin vs citrate)
Quenot 2013 Comparisons do not fulfil inclusion criteria (heparin vs citrate)
Rajani 1979 Interventions do not fulfil inclusion criteria (warfarin vs low molecular weight heparin)
Randon 2006 Comparisons do not fulfil inclusion criteria (heparin vs non-needle system)
Ray 1999 Comparison interventions do not fulfil inclusion criteria (heparin vs urokinase)
Reichardt 2002 Interventions do not fulfil inclusion criteria (systemic heparin)
Rijnders 2005 Interventions do not fulfil inclusion criteria (antibiotics vs placebo)
Roberts 1994 Peripheral catheters were used
Ruggiero 1983 Interventions do not fulfil inclusion criteria (heparin continuous)
Sanders 2008 Comparison interventions do not fulfil inclusion criteria (heparin vs ethanol)
Sang Sook 2012 Arterial catheters were used
Saxena 2006 Comparison does not fulfil inclusion criteria (heparin vs cefotaxime + heparin)
Saxena 2006a Comparison does not fulfil inclusion criteria (heparin vs cefotaxime + heparin)
Scherr 2002 Arterial catheters were used
Schouten 2013 Comparisons do not fulfil inclusion criteria (heparin vs citrate)
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Schroder 2008 Comparisons do not fulfil inclusion criteria (heparin vs taurolidine)
Shirzad 2013 Comparisons do not fulfil inclusion criteria (heparin vs heparin + cefazolin)
Silva 2008 Interventions do not fulfil inclusion criteria (antibiotic ointment vs antibiotic lock)
Silva 2013 Comparison does not fulfil inclusion criteria (heparin vs heparin + cefazolin + gentamicin)
Smith 1990 Interventions do not fulfil inclusion criteria (heparin lock left in place)
Sofroniadou 2012 Comparison does not fulfil inclusion criteria (heparin vs heparin + vancomycin vs heparin +
linezolid)
Solomon 2001 Comparison does not fulfil inclusion criteria (heparin vs urokinase)
Solomon 2010 Comparison does not fulfil inclusion criteria (heparin vs taurolidine + citrate)
Stas 2001 Comparison does not fulfil inclusion criteria (heparin vs citrate)
Thomson 2011 Comparison interventions do not fulfil inclusion criteria (different concentrations of heparin)
Thurlimann 1992 Interventions do not fulfil inclusion criteria (peripheral catheters)
Tolar 1996 Interventions do not fulfil inclusion criteria (no heparin use)
Trottier 1995 Interventions do not fulfil inclusion criteria (different catheterisation sites)
Tuncali 2005 Interventions do not fulfil inclusion criteria (arterial catheters, continuous flushing)
Tuten 1991 Peripheral catheters were used
Venditto 2010 Comparison interventions do not fulfil inclusion criteria (heparin vs citrate vs heparin + gentamicin)
Vercaigne 2011 Comparisons do not fulfil inclusion criteria (heparin vs citrate + ethanol)
Verso 2005 Interventions do not fulfil inclusion criteria (systemic enoxaparin)
Wang 2012 Peripheral catheters were used
Warkentin 1998 Although designed as an RCT, we contacted study authors as insufficient information was provided
and the study has never been published; we received no response
Weijmer 2005 Comparison does not fulfil inclusion criteria (heparin vs citrate)
Whitta 2006 Interventions do not fulfil inclusion criteria (continuous heparin flushing)
Witkovski 2010 Arterial catheters were used
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Wolf 2011 Comparisons do not fulfil inclusion criteria (heparin vs ethanol)
Wong 2009 Interventions do not fulfil inclusion criteria (heparin 2500 IU/mL vs heparin 500 IU/mL vs sodium
citrate + glucose)
Xu 2017 Peripheral catheters were used
Young 2009 Interventions do not fulfil inclusion criteria (warfarin)
Zacharski 2005 Interventions do not fulfil inclusion criteria (warfarin vs low molecular weight heparin)
Zhang 2009 Interventions do not fulfil inclusion criteria (heparin vs gentamicin + heparin)
Ziyaeifard 2015 Data were not stratified by arterial and central venous catheters. We received no response to request
for additional data, so we were unable to use the published data
EDTA: ethylenediaminetetraacetic acid.
RCT: randomised controlled trial.
SC: subcutaneous.
Characteristics of studies awaiting assessment [ordered by study ID]
Klein 2017
Methods
Participants
Interventions
Outcomes
Notes Publication is abstract only, does not contain data, further information is required from study authors
Klein 2018
Methods
Participants
Interventions
Outcomes
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Notes Awaiting full copy of publication, abstract does not contain data, further information is required from study authors
Characteristics of ongoing studies [ordered by study ID]
NCT02354118
Trial name or title Maintaining Patency in Implanted Port Catheters
Methods RCT
Participants Estimated enrolment: 396
Inclusion criteria:
• Able to read and understand English
• Has an implanted port in place less than 1 year
• Evidence of a patent (unobstructed) port catheter before enrolment in the study
• Is receiving active treatment (i.e. is receiving a therapeutic drug through the implanted port)
• Current treatment protocol projected to continue for a minimum of 3 months
• Anticipates receiving care at identified centres for 12 months following enrolment in the study
• Does not receive care for implanted port at any other facility
Interventions Control group (active comparator): control group will have port catheters flushed with 20 mL saline and after
with 5 mL heparin 100 units/mL each 3 months
Intervention group (experimental): saline-only catheter flush. Intervention group will have port catheters
flushed with saline only
Outcomes Occlusion, days without obstruction, safety
Starting date 29 January 2015
Contact information Partusch S
Notes Recruiting participants
NCT02923830
Trial name or title Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes
Methods RCT open-label phase 4
Participants 396 participants
Inclusion criteria:
• Able to read and understand English
• Has a BioFlo implanted port in place less than 1 year
• Evidence of a patent BioFlo port catheter before enrolment in the study
• Is receiving active treatment (i.e. is receiving a therapeutic drug) through the BioFlo implanted port
• Current treatment protocol projected to continue for a minimum of 3 months
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• Anticipates receiving care at identified centres for 12 months following enrolment in the study
• Does not receive care for BioFlo implanted port at any other facility
Interventions Active comparator: heparinised saline catheter flush; port catheters flushed with 20 mL saline + 5 mL heparin
100 units/mL
Experimental: saline-only catheter flush: port catheters flushed with saline only
Outcomes Occlusion, days without obstruction, safety
Starting date 30 September 2016
Contact information Partusch S
Notes Recruiting participants
RBR-3ht499
Trial name or title Efetividade da Solução de Heparina na Prevenção de Oclusão do Cateter de Hickman®: Ensaio Clínico
[Effectiveness of Heparin Solution in Preventing Hickman® Catheter Occlusion: Clinical Trial]
Methods RCT triple-blind
Participants 100 patients with CVC who need haematopoietic stem cell transplantation
Interventions Solutions to be compared will be 0.9% saline solution and heparin solution 50 IU/mL. There will be 50
participants for group A and 50 participants for group B. After insertion of the catheter, each time it is
deprecated, it will be blocked with solution A or B, according to randomisation
Outcomes “The evaluation will be done when opening the catheter path, where it should be aspirated pre-defined
intraluminal content, being 2 mL for adult and 1 mL for child. The reflux should occur in up to four
attempts, then: open the clamp and aspirate the contents; Inspect mechanical causes such as fracture, torsion
or traction; ask the patient to inhale and hold the air; And hyperextend the patient’s neck and ask to place the
corresponding hand on the side of the catheter insert in the occipital region. If there is no reflux after the four
attempts described above, the catheter must be rinsed without forcing. If, when injecting saline solution 0.9%
into the lumen of the catheter, the flow occurs without resistance, the follow-up is closed by occlusion without
reflux. Or, if after the four attempts of reflux, the lavage with 0.9% saline is not performed in the lumen of
the catheter, that if resistance / pressure is present for the washing, the follow-up of the route by complete
occlusion. In the cases of complete occlusion or occlusion without reflux, the follow-up is completed, the
standardized clearing maneuver is performed in the service and afterwards the standard locking solution of
the service is used. The procedure will be the same for both groups.”
Starting date • Planned date of first enrolment: 22-03-2017
• Planned date of last enrolment: 20-10-2017
Contact information Sandra Regina da Silva
Address: Rua Congo, 271
Pinhais
Brazil 8320-320
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RBR-3ht499 (Continued)
Phone: +55 (41) 99199.2470
E-mail: sandra silvah@yahoo.com.br
Universidade Federal do Paraná
Notes
CVC: central venous catheter.
RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. All occlusions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All studies 10 2697 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.51, 0.95]
1.1 Participants 7 1672 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.58, 1.08]
1.2 Catheters 3 1025 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.29, 0.95]
Comparison 2. Occlusion of CVCs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occlusion of CVCs (unit of
analysis participant)
7 1672 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.58, 1.08]
2 Occlusion of CVCs (unit of
analysis catheter)
3 1025 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.29, 0.95]
3 Occlusion of CVCs (unit of
analysis line access)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. All patency
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All studies 6 1788 Mean Difference (IV, Random, 95% CI) 0.44 [-0.10, 0.99]
1.1 Participants 4 1036 Mean Difference (IV, Random, 95% CI) 0.66 [-0.66, 1.97]
1.2 Catheters 2 752 Mean Difference (IV, Random, 95% CI) 0.40 [-0.20, 0.99]
Comparison 4. Duration of catheter patency
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Duration of catheter patency
(unit of analysis participant)
4 1036 Mean Difference (IV, Random, 95% CI) 0.66 [-0.66, 1.97]
2 Duration of catheter patency
(unit of analysis catheter)
2 752 Mean Difference (IV, Random, 95% CI) 0.40 [-0.20, 0.99]
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Comparison 5. Safety
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CVC-related sepsis 2 1097 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.03, 19.54]
2 Mortality 3 1100 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.44, 1.31]
3 Haemorrhage from any site 4 1245 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.57, 3.07]
4 Heparin-induced
thrombocytopaenia
3 443 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.01, 4.27]
5 CVC-related thrombosis 3 1527 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.77, 2.02]
Comparison 6. Sensitivity analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occlusion of CVCs related to
quality
10 2697 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.51, 0.95]
1.1 Poor or unclear allocation
concealment
6 666 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.16, 0.95]
1.2 Good allocation
concealment
4 2031 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.51, 1.05]
2 Occlusion of CVCs related to
weight of studies
6 870 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.30, 0.91]
2.1 Without most weighted
study (Goosens)
6 870 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.30, 0.91]
3 All occlusions effect size 10 Risk Ratio (Random, 95% CI) 0.78 [0.62, 0.98]
3.1 Participants 7 Risk Ratio (Random, 95% CI) 0.84 [0.65, 1.08]
3.2 Catheters 3 Risk Ratio (Random, 95% CI) 0.54 [0.31, 0.96]
4 All patency effect size 6 Mean Difference (Random, 95% CI) 0.44 [-0.10, 0.99]
4.1 Participants 4 Mean Difference (Random, 95% CI) 0.66 [-0.66, 1.97]
4.2 Catheter 2 Mean Difference (Random, 95% CI) 0.40 [-0.20, 0.99]
Comparison 7. Analysis of subgroups
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occlusion of CVCs oncology vs
non-oncology participants
10 2697 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.51, 0.95]
1.1 Non-oncological
participants
8 1465 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.30, 0.77]
1.2 Oncological participants 2 1232 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.69, 1.19]
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2 Occlusion of CVCs number
of lumens (unit of analysis
participants)
6 1582 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.68, 1.15]
2.1 One lumen 3 1334 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.57, 1.26]
2.2 More than one lumen 3 248 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.15, 2.59]
3 All occlusions - heparin
concentration
10 2497 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.32, 1.20]
3.1 Heparin ≥ 1000 IU/mL 3 214 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.14, 1.25]
3.2 Heparin < 1000 IU/mL 7 2283 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.31, 1.34]
4 Occlusion of CVCs and time to
follow-up
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Less than one month 8 1465 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.30, 0.77]
4.2 One month or longer 2 1232 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.69, 1.19]
Analysis 1.1. Comparison 1 All occlusions, Outcome 1 All studies.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 1 All occlusions
Outcome: 1 All studies
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Participants
Beigi 2014 0/50 0/50 Not estimable
Bowers 2008 0/52 3/50 1.1 % 0.14 [ 0.01, 2.60 ]
Dal Molin 2015 (1) 10/217 15/213 13.4 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 73/398 78/404 49.0 % 0.95 [ 0.71, 1.27 ]
Kaneko 2004 1/22 1/26 1.3 % 1.18 [ 0.08, 17.82 ]
Lyons 2014 (2) 6/62 7/28 8.7 % 0.39 [ 0.14, 1.05 ]
Mahesh 2014 2/50 4/50 3.4 % 0.50 [ 0.10, 2.61 ]
Subtotal (95% CI) 851 821 76.9 % 0.79 [ 0.58, 1.08 ]
Total events: 92 (Heparin), 108 (NS)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.35, df = 5 (P = 0.37); I2 =7%
Test for overall effect: Z = 1.46 (P = 0.15)
2 Catheters
Pumarola 2007 0/125 0/125 Not estimable
Rabe 2002 3/33 9/33 6.1 % 0.33 [ 0.10, 1.12 ]
Schallom 2012 12/314 25/395 17.0 % 0.60 [ 0.31, 1.18 ]
0.05 0.2 1 5 20
Favours Heparin Favours NS
(Continued . . . )
62Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 472 553 23.1 % 0.53 [ 0.29, 0.95 ]
Total events: 15 (Heparin), 34 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
Total (95% CI) 1323 1374 100.0 % 0.70 [ 0.51, 0.95 ]
Total events: 107 (Heparin), 142 (NS)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.11, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Chi2 = 1.43, df = 1 (P = 0.23), I2 =30%
0.05 0.2 1 5 20
Favours Heparin Favours NS
(1) The study included partial occlusions (when fluids can be flushed freely but blood cannot be withdrawn) and total occlusion (defined as impossibility to flush and draw
blood). Only one total occlusion was reported in the saline group
(2) We combined results from low and high dose heparin groups
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Analysis 2.1. Comparison 2 Occlusion of CVCs, Outcome 1 Occlusion of CVCs (unit of analysis participant).
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 2 Occlusion of CVCs
Outcome: 1 Occlusion of CVCs (unit of analysis participant)
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beigi 2014 0/50 0/50 Not estimable
Bowers 2008 0/52 3/50 1.2 % 0.14 [ 0.01, 2.60 ]
Dal Molin 2015 (1) 10/217 15/213 15.1 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 73/398 78/404 69.3 % 0.95 [ 0.71, 1.27 ]
Kaneko 2004 1/22 1/26 1.4 % 1.18 [ 0.08, 17.82 ]
Lyons 2014 (2) 6/62 7/28 9.5 % 0.39 [ 0.14, 1.05 ]
Mahesh 2014 2/50 4/50 3.6 % 0.50 [ 0.10, 2.61 ]
Total (95% CI) 851 821 100.0 % 0.79 [ 0.58, 1.08 ]
Total events: 92 (Heparin), 108 (NS)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.35, df = 5 (P = 0.37); I2 =7%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Heparin Favours NS
(1) The study included partial occlusions (when fluids can be flushed freely but blood cannot be withdrawn) and total occlusion (defined as impossibility to flush and draw
blood). Only one total occlusion was reported in the saline group
(2) We combined results from low and high dose heparin groups
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Analysis 2.2. Comparison 2 Occlusion of CVCs, Outcome 2 Occlusion of CVCs (unit of analysis catheter).
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 2 Occlusion of CVCs
Outcome: 2 Occlusion of CVCs (unit of analysis catheter)
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pumarola 2007 0/125 0/125 Not estimable
Rabe 2002 3/33 9/33 23.5 % 0.33 [ 0.10, 1.12 ]
Schallom 2012 12/314 25/395 76.5 % 0.60 [ 0.31, 1.18 ]
Total (95% CI) 472 553 100.0 % 0.53 [ 0.29, 0.95 ]
Total events: 15 (Heparin), 34 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Heparin Favours NS
Analysis 2.3. Comparison 2 Occlusion of CVCs, Outcome 3 Occlusion of CVCs (unit of analysis line access).
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 2 Occlusion of CVCs
Outcome: 3 Occlusion of CVCs (unit of analysis line access)
Study or subgroup Heparin NS Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Goosens 2013 115/3026 109/3111 1.08 [ 0.84, 1.40 ]
0.05 0.2 1 5 20
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Analysis 3.1. Comparison 3 All patency, Outcome 1 All studies.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 3 All patency
Outcome: 1 All studies
Study or subgroup Heparin NS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants
Bowers 2008 52 2.9 (5.7) 50 2.1 (4) 8.2 % 0.80 [ -1.11, 2.71 ]
Goosens 2013 398 150.9 (40.7) 404 152.4 (37.9) 1.0 % -1.50 [ -6.94, 3.94 ]
Heidari 2015 42 15.47 (3.99) 42 14.45 (5.56) 6.9 % 1.02 [ -1.05, 3.09 ]
Kaneko 2004 22 17.3 (8.85) 26 18.1 (10.15) 1.0 % -0.80 [ -6.18, 4.58 ]
Subtotal (95% CI) 514 522 17.1 % 0.66 [ -0.66, 1.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
2 Catheters
Pumarola 2007 25 4.87 (5) 18 4.55 (4) 4.1 % 0.32 [ -2.37, 3.01 ]
Schallom 2012 314 8 (4) 395 7.6 (4.3) 78.8 % 0.40 [ -0.21, 1.01 ]
Subtotal (95% CI) 339 413 82.9 % 0.40 [ -0.20, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 853 935 100.0 % 0.44 [ -0.10, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.15, df = 5 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
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Analysis 4.1. Comparison 4 Duration of catheter patency, Outcome 1 Duration of catheter patency (unit of
analysis participant).
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 4 Duration of catheter patency
Outcome: 1 Duration of catheter patency (unit of analysis participant)
Study or subgroup Heparin NS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bowers 2008 52 2.9 (5.7) 50 2.1 (4) 47.7 % 0.80 [ -1.11, 2.71 ]
Goosens 2013 398 150.9 (40.7) 404 152.4 (37.9) 5.8 % -1.50 [ -6.94, 3.94 ]
Heidari 2015 42 15.47 (3.99) 42 14.45 (5.56) 40.4 % 1.02 [ -1.05, 3.09 ]
Kaneko 2004 22 17.3 (8.85) 26 18.1 (10.15) 6.0 % -0.80 [ -6.18, 4.58 ]
Total (95% CI) 514 522 100.0 % 0.66 [ -0.66, 1.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Duration of catheter patency, Outcome 2 Duration of catheter patency (unit of
analysis catheter).
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 4 Duration of catheter patency
Outcome: 2 Duration of catheter patency (unit of analysis catheter)
Study or subgroup Heparin NS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pumarola 2007 25 4.87 (5) 18 4.55 (4) 4.9 % 0.32 [ -2.37, 3.01 ]
Schallom 2012 314 8 (4) 395 7.6 (4.3) 95.1 % 0.40 [ -0.21, 1.01 ]
Total (95% CI) 339 413 100.0 % 0.40 [ -0.20, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Safety, Outcome 1 CVC-related sepsis.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 5 Safety
Outcome: 1 CVC-related sepsis
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Goosens 2013 (1) 6/398 2/404 56.8 % 3.05 [ 0.62, 15.00 ]
Schallom 2012 0/145 4/150 43.2 % 0.11 [ 0.01, 2.12 ]
Total (95% CI) 543 554 100.0 % 0.74 [ 0.03, 19.54 ]
Total events: 6 (Heparin), 6 (NS)
Heterogeneity: Tau2 = 4.25; Chi2 = 3.96, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Heparin Favours NS
(1) Staphylococcus aureus 2, Staphylococcus epidermidis 3, Candida glabatra 1 in heparin group and Staphylococcus epidermidis 1 and Staphylococcus homini 1 in saline
group
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Analysis 5.2. Comparison 5 Safety, Outcome 2 Mortality.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 5 Safety
Outcome: 2 Mortality
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Goosens 2013 20/398 28/404 94.8 % 0.73 [ 0.42, 1.27 ]
Kaneko 2004 0/22 0/26 Not estimable
Pumarola 2007 2/125 1/125 5.2 % 2.00 [ 0.18, 21.78 ]
Total (95% CI) 545 555 100.0 % 0.76 [ 0.44, 1.31 ]
Total events: 22 (Heparin), 29 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Safety, Outcome 3 Haemorrhage from any site.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 5 Safety
Outcome: 3 Haemorrhage from any site
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beigi 2014 4/50 3/50 34.2 % 1.33 [ 0.31, 5.65 ]
Goosens 2013 0/398 0/404 Not estimable
Kaneko 2004 5/22 5/26 58.8 % 1.18 [ 0.39, 3.56 ]
Schallom 2012 1/145 0/150 7.0 % 3.10 [ 0.13, 75.55 ]
Total (95% CI) 615 630 100.0 % 1.32 [ 0.57, 3.07 ]
Total events: 10 (Heparin), 8 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Safety, Outcome 4 Heparin-induced thrombocytopaenia.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 5 Safety
Outcome: 4 Heparin-induced thrombocytopaenia
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kaneko 2004 0/22 0/26 Not estimable
Mahesh 2014 0/50 0/50 Not estimable
Schallom 2012 0/145 2/150 100.0 % 0.21 [ 0.01, 4.27 ]
Total (95% CI) 217 226 100.0 % 0.21 [ 0.01, 4.27 ]
Total events: 0 (Heparin), 2 (NS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Heparin Favours NS
72Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 Safety, Outcome 5 CVC-related thrombosis.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 5 Safety
Outcome: 5 CVC-related thrombosis
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dal Molin 2015 1/217 0/213 2.3 % 2.94 [ 0.12, 71.89 ]
Goosens 2013 13/398 11/404 37.5 % 1.20 [ 0.54, 2.65 ]
Schallom 2012 19/145 16/150 60.2 % 1.23 [ 0.66, 2.29 ]
Total (95% CI) 760 767 100.0 % 1.24 [ 0.77, 2.02 ]
Total events: 33 (Heparin), 27 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Sensitivity analysis, Outcome 1 Occlusion of CVCs related to quality.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 6 Sensitivity analysis
Outcome: 1 Occlusion of CVCs related to quality
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Poor or unclear allocation concealment
Pumarola 2007 0/125 0/125 Not estimable
Beigi 2014 0/50 0/50 Not estimable
Bowers 2008 0/52 3/50 1.1 % 0.14 [ 0.01, 2.60 ]
Rabe 2002 3/33 9/33 6.1 % 0.33 [ 0.10, 1.12 ]
Mahesh 2014 2/50 4/50 3.4 % 0.50 [ 0.10, 2.61 ]
Kaneko 2004 1/22 1/26 1.3 % 1.18 [ 0.08, 17.82 ]
Subtotal (95% CI) 332 334 11.8 % 0.39 [ 0.16, 0.95 ]
Total events: 6 (Heparin), 17 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
2 Good allocation concealment
Lyons 2014 6/62 7/28 8.7 % 0.39 [ 0.14, 1.05 ]
Schallom 2012 12/314 25/395 17.0 % 0.60 [ 0.31, 1.18 ]
Dal Molin 2015 (1) 10/217 15/213 13.4 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 73/398 78/404 49.0 % 0.95 [ 0.71, 1.27 ]
Subtotal (95% CI) 991 1040 88.2 % 0.74 [ 0.51, 1.05 ]
Total events: 101 (Heparin), 125 (NS)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.32, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 1.68 (P = 0.093)
Total (95% CI) 1323 1374 100.0 % 0.70 [ 0.51, 0.95 ]
Total events: 107 (Heparin), 142 (NS)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.11, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Chi2 = 1.65, df = 1 (P = 0.20), I2 =40%
0.05 0.2 1 5 20
Favours Heparin Favours NS
(1) The study included partial occlusions (when fluids can be flushed freely but blood cannot be withdrawn) and total occlusion (defined as impossibility to flush and draw
blood). Only one total occlusion was reported in the saline group
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Analysis 6.2. Comparison 6 Sensitivity analysis, Outcome 2 Occlusion of CVCs related to weight of studies.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 6 Sensitivity analysis
Outcome: 2 Occlusion of CVCs related to weight of studies
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Without most weighted study (Goosens)
Beigi 2014 0/50 0/50 Not estimable
Bowers 2008 0/52 3/50 3.5 % 0.14 [ 0.01, 2.60 ]
Dal Molin 2015 10/217 15/213 50.4 % 0.65 [ 0.30, 1.42 ]
Kaneko 2004 1/22 1/26 4.1 % 1.18 [ 0.08, 17.82 ]
Lyons 2014 6/62 7/28 30.8 % 0.39 [ 0.14, 1.05 ]
Mahesh 2014 2/50 4/50 11.2 % 0.50 [ 0.10, 2.61 ]
Total (95% CI) 453 417 100.0 % 0.52 [ 0.30, 0.91 ]
Total events: 19 (Heparin), 30 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.82, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Sensitivity analysis, Outcome 3 All occlusions effect size.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 6 Sensitivity analysis
Outcome: 3 All occlusions effect size
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Participants
Bowers 2008 -1.984 (1.4991) 0.6 % 0.14 [ 0.01, 2.60 ]
Lyons 2014 -0.9491 (0.5076) 5.4 % 0.39 [ 0.14, 1.05 ]
Mahesh 2014 -0.6931 (0.8426) 2.0 % 0.50 [ 0.10, 2.61 ]
Dal Molin 2015 -0.4241 (0.3967) 8.9 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 -0.0513 (0.1467) 65.1 % 0.95 [ 0.71, 1.27 ]
Beigi 2014 0 (1.4) 0.7 % 1.00 [ 0.06, 15.55 ]
Kaneko 2004 0.1671 (1.3842) 0.7 % 1.18 [ 0.08, 17.82 ]
Subtotal (95% CI) 83.5 % 0.84 [ 0.65, 1.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.34, df = 6 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Catheters
Rabe 2002 -1.098 (0.619) 3.7 % 0.33 [ 0.10, 1.12 ]
Schallom 2012 -0.5045 (0.34) 12.1 % 0.60 [ 0.31, 1.18 ]
Pumarola 2007 0 (1.4) 0.7 % 1.00 [ 0.06, 15.55 ]
Subtotal (95% CI) 16.5 % 0.54 [ 0.31, 0.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 100.0 % 0.78 [ 0.62, 0.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.13, df = 9 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.035)
Test for subgroup differences: Chi2 = 1.88, df = 1 (P = 0.17), I2 =47%
0.05 0.2 1 5 20
Favours Heparin Favours NS
76Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.4. Comparison 6 Sensitivity analysis, Outcome 4 All patency effect size.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 6 Sensitivity analysis
Outcome: 4 All patency effect size
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Participants
Goosens 2013 -1.5 (2.778) 1.0 % -1.50 [ -6.94, 3.94 ]
Kaneko 2004 -0.8 (2.742) 1.0 % -0.80 [ -6.17, 4.57 ]
Bowers 2008 0.8 (0.972) 8.2 % 0.80 [ -1.11, 2.71 ]
Heidari 2015 1.02 (1.056) 6.9 % 1.02 [ -1.05, 3.09 ]
Subtotal (95% CI) 17.1 % 0.66 [ -0.66, 1.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
2 Catheter
Pumarola 2007 0.32 (1.374) 4.1 % 0.32 [ -2.37, 3.01 ]
Schallom 2012 0.4 (0.3127) 78.8 % 0.40 [ -0.21, 1.01 ]
Subtotal (95% CI) 82.9 % 0.40 [ -0.20, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 100.0 % 0.44 [ -0.10, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 5 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
-10 -5 0 5 10
Favours NS Favours Heparin
77Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.1. Comparison 7 Analysis of subgroups, Outcome 1 Occlusion of CVCs oncology vs non-oncology
participants.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 7 Analysis of subgroups
Outcome: 1 Occlusion of CVCs oncology vs non-oncology participants
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-oncological participants
Beigi 2014 0/50 0/50 Not estimable
Bowers 2008 0/52 3/50 1.1 % 0.14 [ 0.01, 2.60 ]
Kaneko 2004 1/22 1/26 1.3 % 1.18 [ 0.08, 17.82 ]
Lyons 2014 (1) 6/62 7/28 8.7 % 0.39 [ 0.14, 1.05 ]
Mahesh 2014 2/50 4/50 3.4 % 0.50 [ 0.10, 2.61 ]
Pumarola 2007 0/125 0/125 Not estimable
Rabe 2002 3/33 9/33 6.1 % 0.33 [ 0.10, 1.12 ]
Schallom 2012 12/314 25/395 17.0 % 0.60 [ 0.31, 1.18 ]
Subtotal (95% CI) 708 757 37.6 % 0.48 [ 0.30, 0.77 ]
Total events: 24 (Heparin), 49 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.10, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
2 Oncological participants
Dal Molin 2015 (2) 10/217 15/213 13.4 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 73/398 78/404 49.0 % 0.95 [ 0.71, 1.27 ]
Subtotal (95% CI) 615 617 62.4 % 0.91 [ 0.69, 1.19 ]
Total events: 83 (Heparin), 93 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 1323 1374 100.0 % 0.70 [ 0.51, 0.95 ]
Total events: 107 (Heparin), 142 (NS)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.11, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Chi2 = 5.18, df = 1 (P = 0.02), I2 =81%
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(1) We combined results from low and high dose heparin groups
(2) The study included partial occlusions (when fluids can be flushed freely but blood cannot be withdrawn) and total occlusion (defined as impossibility to flush and draw
blood). Only one total occlusion was reported in the saline group
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Analysis 7.2. Comparison 7 Analysis of subgroups, Outcome 2 Occlusion of CVCs number of lumens (unit
of analysis participants).
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 7 Analysis of subgroups
Outcome: 2 Occlusion of CVCs number of lumens (unit of analysis participants)
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 One lumen
Bowers 2008 0/52 3/50 0.8 % 0.14 [ 0.01, 2.60 ]
Dal Molin 2015 10/217 15/213 11.5 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 73/398 78/404 84.2 % 0.95 [ 0.71, 1.27 ]
Subtotal (95% CI) 667 667 96.5 % 0.85 [ 0.57, 1.26 ]
Total events: 83 (Heparin), 96 (NS)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.38, df = 2 (P = 0.30); I2 =16%
Test for overall effect: Z = 0.82 (P = 0.41)
2 More than one lumen
Beigi 2014 0/50 0/50 Not estimable
Mahesh 2014 2/50 4/50 2.6 % 0.50 [ 0.10, 2.61 ]
Kaneko 2004 1/22 1/26 0.9 % 1.18 [ 0.08, 17.82 ]
Subtotal (95% CI) 122 126 3.5 % 0.63 [ 0.15, 2.59 ]
Total events: 3 (Heparin), 5 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 789 793 100.0 % 0.88 [ 0.68, 1.15 ]
Total events: 86 (Heparin), 101 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.69), I2 =0.0%
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Analysis 7.3. Comparison 7 Analysis of subgroups, Outcome 3 All occlusions - heparin concentration.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 7 Analysis of subgroups
Outcome: 3 All occlusions - heparin concentration
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Heparin≥ 1000 IU/mL
Beigi 2014 (1) 0/50 0/50 Not estimable
Rabe 2002 (2) 3/33 9/33 11.8 % 0.33 [ 0.10, 1.12 ]
Kaneko 2004 (3) 1/22 1/26 4.6 % 1.18 [ 0.08, 17.82 ]
Subtotal (95% CI) 105 109 16.4 % 0.41 [ 0.14, 1.25 ]
Total events: 4 (Heparin), 10 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Heparin < 1000 IU/mL
Pumarola 2007 (4) 0/125 0/125 Not estimable
Bowers 2008 (5) 0/52 3/50 4.1 % 0.14 [ 0.01, 2.60 ]
Lyons 2014 (6) 3/32 4/14 10.7 % 0.33 [ 0.08, 1.28 ]
Lyons 2014 (7) 3/30 3/14 10.0 % 0.47 [ 0.11, 2.03 ]
Mahesh 2014 (8) 2/50 4/50 8.8 % 0.50 [ 0.10, 2.61 ]
Schallom 2012 (9) 12/314 25/395 16.1 % 0.60 [ 0.31, 1.18 ]
Dal Molin 2015 (10) 10/217 15/213 15.3 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 (11) 73/198 78/404 18.7 % 1.91 [ 1.46, 2.50 ]
Subtotal (95% CI) 1018 1265 83.6 % 0.65 [ 0.31, 1.34 ]
Total events: 103 (Heparin), 132 (NS)
Heterogeneity: Tau2 = 0.59; Chi2 = 25.90, df = 6 (P = 0.00023); I2 =77%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 1123 1374 100.0 % 0.62 [ 0.32, 1.20 ]
Total events: 107 (Heparin), 142 (NS)
Heterogeneity: Tau2 = 0.60; Chi2 = 30.99, df = 8 (P = 0.00014); I2 =74%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
0.05 0.2 1 5 20
Favours Heparin Favours NS
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(1) 1000 IU
(2) 2500 IU
(3) 2000 IU
(4) 100 IU
(5) 300 IU
(6) High doses were defined as 300 IU heparin and low doses as 50 IU heparin. We split the events of the saline group
(7) High doses were defined as 300 IU heparin and low doses as 50 IU heparin. We split the events of the saline group
(8) 30 IU
(9) 30 IU
(10) 250 IU. The study included partial occlusions (when fluids can be flushed freely but blood cannot be withdrawn) and total occlusion (defined as impossibility to flush
and draw blood). Only one total occlusion was reported in the saline group
(11) 300 IU
Analysis 7.4. Comparison 7 Analysis of subgroups, Outcome 4 Occlusion of CVCs and time to follow-up.
Review: Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
Comparison: 7 Analysis of subgroups
Outcome: 4 Occlusion of CVCs and time to follow-up
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Less than one month
Beigi 2014 0/50 0/50 Not estimable
Pumarola 2007 0/125 0/125 Not estimable
Bowers 2008 0/52 3/50 2.6 % 0.14 [ 0.01, 2.60 ]
Rabe 2002 3/33 9/33 15.0 % 0.33 [ 0.10, 1.12 ]
Lyons 2014 (1) 6/62 7/28 22.4 % 0.39 [ 0.14, 1.05 ]
Mahesh 2014 2/50 4/50 8.1 % 0.50 [ 0.10, 2.61 ]
Schallom 2012 12/314 25/395 49.0 % 0.60 [ 0.31, 1.18 ]
Kaneko 2004 1/22 1/26 3.0 % 1.18 [ 0.08, 17.82 ]
0.05 0.2 1 5 20
Favours Heparin Favours NS
(Continued . . . )
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(. . . Continued)
Study or subgroup Heparin NS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 708 757 100.0 % 0.48 [ 0.30, 0.77 ]
Total events: 24 (Heparin), 49 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.10, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
2 One month or longer
Dal Molin 2015 (2) 10/217 15/213 12.0 % 0.65 [ 0.30, 1.42 ]
Goosens 2013 73/398 78/404 88.0 % 0.95 [ 0.71, 1.27 ]
Subtotal (95% CI) 615 617 100.0 % 0.91 [ 0.69, 1.19 ]
Total events: 83 (Heparin), 93 (NS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 5.18, df = 1 (P = 0.02), I2 =81%
0.05 0.2 1 5 20
Favours Heparin Favours NS
(1) We combined results from low and high dose of heparin groups
(2) The study included partial occlusions (when fluids can be flushed freely but blood cannot be withdrawn) and total occlusion (defined as impossibility to flush and draw
blood). Only one total occlusion was reported in saline group
A D D I T I O N A L T A B L E S
Table 1. Secondary outcomes
Study CVC-related throm-
bosis
CVC-related sepsis Mortality HIT
H NS H NS H NS H NS
Bowers
2008
NR NR NR NR NR NR NR NR
Goosens
2013
13/398 11/404 6/398 2/404 20/398 28/404 NR NR
Kaneko
2004
NR NR NR NR 0 0 0 0
Mahesh
2014
NR NR NR NR NR NR 0 0
Pumarola
2007
NR NR NR NR 2/125 1/125 NR NR
82Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Secondary outcomes (Continued)
Rabe 2002 NR NR NR NR NR NR NR NR
Schallom
2012
19/145 16/150 0/145 4/150 NR NR 0/145 2/150
CVC: central venous catheter.
H: heparin.
HIT: heparin-induced thrombocytopaenia.
NR: not reported.
NS: normal saline (0.9% NaCl).
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Heparin EXPLODE ALL TREES
#2 (hep* or UH or UFH or LMWH):TI,AB,KY
#3 *parin:TI,AB,KY
#4 *paran:TI,AB,KY
#5 #1 OR #2 OR #3 OR #4
#6 MESH DESCRIPTOR Sodium Chloride
#7 MESH DESCRIPTOR Saline Solution, Hypertonic
#8 saline:TI,AB,KY
#9 sodium*:TI,AB,KY
#10 NaCl:TI,AB,KY
#11 #6 OR #7 OR #8 OR #9 OR #10
#12 #5 AND #11
#13 MESH DESCRIPTOR Catheterization, Central Venous
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(Continued)
#14 MESH DESCRIPTOR Catheterization
#15 MESH DESCRIPTOR Catheters, Indwelling
#16 MESH DESCRIPTOR Vascular Access Devices
#17 MESH DESCRIPTOR Central Venous Catheters
#18 catheter*:TI,AB,KY
#19 cannula*:TI,AB,KY
#20 (CVC* or PICC):TI,AB,KY
#21 (venous near3 access):TI,AB,KY
#22 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23 #12 AND #22
Appendix 2. MEDLINE search strategy
1 exp Heparin/
2 (hep$ or UH or UFH or LMWH).ti,ab.
3 Sodium Chloride/
4 Saline Solution, Hypertonic/
5 saline.ti,ab.
6 sodium.ti,ab.
7 NaCl.ti,ab.
8 1 or 2
9 or/3-7
10 8 and 9
11 Catheterization, Central Venous/
12 Catheterization/
13 Catheters, Indwelling/
14 cannul$.ti,ab.
15 catheter$.ti,ab.
16 (CVC or PICC).ti,ab.
17 (venous adj3 access).ti,ab.
18 or/11-17
19 10 and 18
20 randomized controlled trial.pt.
21 controlled clinical trial.pt.
22 randomized.ab.
23 placebo.ab.
24 clinical trials as topic.sh.
25 randomly.ab.
26 trial.ti.
27 or/20-26
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28 exp animals/ not humans.sh.
29 27 not 28
30 19 and 29
Appendix 3. Embase search strategy
1 exp heparin/
2 (hep$ or UH or UFH or LMWH).ti,ab.
3 1 or 2
4 sodium chloride/
5 hypertonic solution/
6 (saline or sodium or NaCl).ti,ab.
7 or/3-6
8 3 and 7
9 central venous catheterization/
10 catheterization/
11 catheter thrombosis/pc [Prevention]
12 intravenous catheter/ or catheter/ or peripherally inserted central venous catheter/
13 (catheter$ or cannul$).ti,ab.
14 (CVC or PICC).ti,ab.
15 (venous adj3 access).ti,ab.
16 or/9-15
17 8 and 16
18 random$.ti,ab.
19 factorial$.ti,ab.
20 (crossover$ or cross over$ or cross-over$).ti,ab.
21 placebo$.ti,ab.
22 (doubl$ adj blind$).ti,ab.
23 (singl$ adj blind$).ti,ab.
24 assign$.ti,ab.
25 allocat$.ti,ab.
26 volunteer$.ti,ab.
27 CROSSOVER PROCEDURE/
28 DOUBLE-BLIND METHOD/
29 RANDOMIZED CONTROLLED TRIALS/
30 SINGLE-BLIND METHOD/
31 or/18-30
32 17 and 31
Appendix 4. CINAHL search strategy
S32 S13 AND S23 AND S31
S31 S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30
S30 TX venous N3 access
S29 TX (CVC or PICC)
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(Continued)
S28 TX catheter*
S27 TX cannul*
S26 (MH “Catheters”)
S25 (MH “Catheterization”)
S24 (MH “Catheterization, Central Venous”)
S23 S21 AND S22
S22 S16 OR S17 OR S18 OR S19 OR S20
S21 S14 OR S15
S20 TX NaCl
S19 TX sodium
S18 TX saline
S17 (MH “Saline Solution, Hypertonic”)
S16 (MH “Sodium Chloride”)
S15 TX (hep* or UH or UFH or LMWH)
S14 (MH “Heparin+”)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12
S12 single blind
S11 double blind
S10 triple blind
S9 latin square
S8 placebo*
S7 (MH “Placebos”)
S6 follow-up stud*
S5 alloca*
S4 random*
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(Continued)
S3 clin* N2 trial*
S2 (MH “Random Assignment”)
S1 (MH “Clinical Trials+”)
Appendix 5. Clinicaltrials.gov search
catheter AND heparin 201 studies found
Appendix 6. International Clinical Trials Registry Platform (WHO database)
heparin AND catheter 53 records for 53 trials found
WH A T ’ S N E W
Last assessed as up-to-date: 11 June 2018.
Date Event Description
11 June 2018 New citation required and conclusions have changed Search updated. Five new studies included, three new ongo-
ing studies identified, seven additional studies excluded and
two studies classed as awaiting classification. Text amended
to reflect current Cochrane policy. Conclusions changed
11 June 2018 New search has been performed Search updated. Five new studies included, three new ongo-
ing studies identified, seven additional studies excluded, and
two studies classed as awaiting classification
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
When we planned the present systematic review, and as a result of clinical considerations, we assumed that the unit of analysis would be
the participant. When we performed the searches, we found that studies also used the catheter or line access (every time a line was used
to provide drugs, blood, etc.) as the unit of analysis. As a result, we analysed separately for each different unit of analysis, in addition
to pooling all studies.
Although we used a fixed-effect model in the previous version of this review, we decided to use a random-effects model for this update,
even when statistical heterogeneity was low. This decision was based on clinical heterogeneity among trials, such as different lengths of
follow-up, different doses for locking heparin, and different co-interventions.
Compared to the previous published version (López-Briz 2014), in keeping with Cochrane recommendations, we removed references
from the list of excluded studies that were systematic reviews, not randomised controlled trials, or trials that included exclusively children
or infants.
A distinction must be made between flushing a catheter, which is done for the purpose of washing out the contents of the catheter,
and locking a catheter, which is done to inject a fluid that is intended to stay in the catheter until next use. To remove any ambiguity
regarding the intention of this review, we have introduced the term ’locking’ instead of ’flushing’.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Catheter Obstruction [statistics & numerical data]; ∗Catheterization, Central Venous; ∗Central Venous Catheters; Anticoagulants
[∗administration&dosage];Heparin [∗ administration&dosage]; SodiumChloride [∗ administration&dosage]; Therapeutic Irrigation
[methods]
MeSH check words
Adult; Humans
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